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ABSTRACT 
 
 
CATHERINE A. PANOZZO:  Patterns of rotavirus vaccine uptake, use, and effectiveness in 
privately-insured US children, 2006-2010 
(Under the direction of M. Alan Brookhart) 
 
          Objectives.  Our study examines predictors and timeliness of rotavirus vaccine 
administration among privately-insured US infants and children from 2006 to 2010.  We also 
calculate direct, indirect, total, and overall rotavirus vaccine effectiveness estimates as well 
as the number of rotavirus and acute gastroenteritis hospitalizations prevented among infants 
and children aged 8 to 20 months. 
          Methods. Bivariate analyses and multivariable log-risk models were used to determine 
predictors of rotavirus vaccine series initiation and completion among infants in the 
MarketScan Research Databases.  Vaccine effectiveness estimates were derived using Cox 
proportional hazards regression, stratifying by calendar year and adjusting for month of birth.  
Incidence rate differences were calculated to determine the absolute number of rotavirus and 
acute gastroenteritis hospitalizations prevented in the cohort.   
          Results.   Most infants received the rotavirus vaccines at the recommended ages, but 
more infants completed the series for monovalent rotavirus vaccine than pentavalent 
rotavirus vaccine or a mix of the two vaccines (87% versus 79% versus 73%). In 
multivariable analyses, the strongest predictors of rotavirus vaccine series initiation and 
completion were
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 receipt of the diphtheria, tetanus and acellular pertussis vaccine (Initiation:  RR=7.50, 95% 
CI=7.30-7.71; Completion: RR=1.26, 95% CI=1.23-1.29), visiting a pediatrician versus 
family physician (Initiation:  RR=1.51, 95% CI=1.49-1.52; Completion:  RR=1.13, 95% 
CI=1.11-1.14), and living in a large metropolitan versus smaller metropolitan, urban, or rural 
area.  Direct vaccine effectiveness of one or more doses of any rotavirus vaccine in 
preventing rotavirus gastroenteritis hospitalizations in children 8 to 20 months ranged from 
87 to 92% for each calendar year, 2007-2010.  Accounting for indirect protection increased 
the total vaccine effectiveness by an additional 3 to 8%.  Failing to account for indirect 
protection underestimated the absolute number of rotavirus gastroenteritis hospitalizations 
prevented in rotavirus-vaccinated children by 1.5 to 5.3-fold. 
          Conclusions.  Accounting for only the direct effectiveness of the rotavirus vaccine 
severely underestimated the total number of rotavirus gastroenteritis hospitalizations 
prevented by the US rotavirus vaccine program.  Interventions to further increase rotavirus 
vaccine coverage should consider targeting family physicians and encouraging completion of 
the vaccine series.   
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CHAPTER I 
REVIEW OF THE LITERATURE 
 
A. Conceptual framework 
Measuring vaccine effectiveness post-market.  Post licensure vaccine effectiveness 
(VE) studies present both challenges and new opportunities.  On one hand, since post 
licensure studies are not generally randomized, identical exposure rates to infections in 
vaccinated and unvaccinated individuals cannot be guaranteed or always measured.   
Additional concerns may include potential biases in case ascertainment, case finding, and the 
validity of vaccination and disease records.(1, 2) On the other hand, the duration of vaccine 
protection, changing epidemiologic patterns of disease, and effectiveness among diverse 
populations, including those vaccinated on alternative schedules, can only be investigated 
post licensure.(3)  
Definitions of vaccine effectiveness.  Most Phase III vaccine efficacy trials focus on 
determining the direct effectiveness of vaccination, generally measured as one minus the 
relative risk in the vaccinated group compared to the unvaccinated group.  Some clinical 
trials and many post-licensure studies also measure herd protection or indirect vaccine 
effectiveness (VE), defined as population-level effects of widespread vaccination on people 
not receiving the vaccine.(1)  Two additional measures of VE, total and overall VE, account 
for both the direct and indirect effectiveness of a vaccine.   Total VE combines the direct and
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indirect VE on individuals receiving the vaccine, while the overall VE weights the average of 
the total VE on individuals receiving the vaccine with the indirect VE on individuals not 
receiving the vaccine.(1)  Total VE can thus be interpreted as the complete benefit of 
vaccination in vaccine recipients and overall VE can be interpreted as the public health 
benefit of vaccination.   Despite challenges in estimating the four types of VE, they are 
essential to understand the real-world impact of a vaccine. (1-3) 
 
B. Historical background 
     Epidemiology of acute gastroenteritis (AGE) and rotavirus gastroenteritis (RGE).  
Although there are many viral, bacterial, and parasitic causes of acute gastroenteritis (AGE) 
in the US, viruses are the most common causes of infectious diarrhea across all age groups, 
and among viruses, rotavirus and norovirus are most frequently observed.(4, 5) Prior to the 
availability of rotavirus vaccines in 2006, AGE accounted for approximately nine percent of 
all hospitalizations among children less than five years of age in the US, and of the 220,000 
children in this age group hospitalized with AGE annually, one-quarter to one-third of these 
hospitalizations were due to rotavirus infection.(6-9)  
In an analysis of privately insured US children during the pre-rotavirus vaccine era, 
2001-2006, the average annual rate of healthcare utilization across all healthcare settings for 
AGE was 1561 per 10,000 children less than five years of age.  The annual hospitalization 
rate for AGE was 50 per 10,000, the emergency department visit rate was 180 per 10,000, 
and outpatient visit rate was 1332 per 10,000 children less than five years of age.  With 
regards to rotavirus gastroenteritis (RGE), during the first five years of life, 1 in 74 children 
were admitted, 1 in 27 required emergency department care, and 1 in 7 were treated
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 in outpatient settings each year.(10)  Health care utilization estimates from another study 
utilizing claims data found that the AGE and RGE hospitalization rates among children less 
than five years of age with Medicaid insurance were nearly double the estimates reported for 
children with private insurance during the pre-rotavirus vaccine period (107 versus 41 per 
10,000); however, outpatient and emergency department estimates among children with both 
insurance types were similar.(11)  
In the pre-rotavirus vaccine era, virtually all children became infected with rotavirus 
by age three years, with illness most commonly occurring between four and twenty-four 
months of age.  Infections during the first three months of life and reinfections among older 
children were more likely to be asymptomatic than primary infections in older infants and 
younger children.(4)  Rotavirus transmission is presumed to occur via the fecal-oral route, 
and shedding has been observed up to 21 days after symptom onset.(4)  In the US, prior to 
the availability of rotavirus vaccines, rotavirus was most prevalent during the winter and 
spring months, generally peaking in March.(12-14)  Since the availability of rotavirus 
vaccines, the typical winter-spring seasonality of rotavirus has shown signs of disruption in 
the US.(14, 15)  
Rotavirus illness usually begins with acute onset of fever and vomiting followed by water 
diarrhea with 10 to 20 bowel movements per day.(16)  Such symptoms generally persist for 
three to eight days.(4)  No specific antiviral therapy is available so treatment generally 
consists of oral or parenteral fluids to prevent and correct dehydration.(17)  Dehydration and 
electrolyte disturbances are the major complications of rotavirus infection, and are most 
common in young infants.(4)  Worldwide, complications from rotavirus infection 
approximately 453,000 deaths annually, or six percent of all deaths in children less than five 
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years of age.(18)  In the US, rotavirus infections are not a major cause of mortality since 
therapy for dehydration is readily available.(19) 
  History of rotavirus vaccines.  The first rotavirus vaccine that was licensed and 
recommend for routine use in US infants was rhesus rotavirus vaccine, tetravalent (RRV-
TV), or Rotashield (Wyeth).  It was composed of four live viruses, including three 
reassortants expressing either G1, G2, or G4 proteins, and the native G3P[3] strain.(20)   
RRV-TV was an oral vaccine, given as a three dose series at ages two, four, and six 
months.(20)  After approximately one year of availability (1998-1999), the recommendation 
to routinely vaccinate infants with RRV-TV was withdrawn due to its association with 
intussusception, a type of bowel obstruction that occurs when the bowel folds in on itself 
(relative risk, 1.6 – 1.8).(21-23) 
     Due to the experience of RRV-TV, a major safety concern when developing new 
rotavirus vaccines was their potential association with intussusception.(24)  Although two 
large clinical trials (>60,000 infants) powered to assess intussusception risk at a magnitude 
similar to that of RRV-TV did not find an increased risk of intussusception after vaccination 
with either of the two currently available rotavirus vaccines, two post-marketing studies  
found a potential increased risk of intussusception following rotavirus vaccination with 
monovalent rotavirus vaccine (RV1), and one of these studies also found an increased risk of 
intussusception after pentavalent rotavirus vaccine (RV5) vaccination.(25-34) However, 
neither of these studies was conducted in the US, and the increased risk of intussusception 
was not consistent for a given dose across the different populations of Mexican, Brazilian, 
and Australian infants.(25, 26)  To-date, RV5 and RV1 continue to be recommended for US 
infants.  
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     RV5 was licensed and recommend in February 2006, and RV1 was licensed in April 
2008 and recommended in June 2008 for routine use among US infants by the Advisory 
Committee on Immunization Practices (ACIP).(35, 36)   RV5 contains five reassortant 
rotaviruses developed from human and bovine parent  strains that express proteins from 
serotypes G1, G2, G3,  G4, and P1A[8], and RV1 consists of a single attenuated human 
rotavirus strain of the G1P1A[8] serotype.  Both are live, oral vaccines, but RV5 requires 
three doses administered at ages two, four, and six months and elicits mainly a homotypic 
immune  response, while RV1 requires just two doses administered at ages two and four 
months and is thought to elicit both a homotypic and heterotypic immune response.(36)  
On March 22, 2010 the Food and Drug Administration (FDA) recommend that 
physicians suspend the use of RV1 after academic researchers discovered that the vaccine 
contained DNA from porcine circovirus 1 (PCV1).(37)  Although the FDA emphasized that 
there were no known safety risks associated with PCV1 contamination, they advised 
physicians to switch to RV5 which was later found to be contaminated with PCV1 and 
porcine circovirus 2 (PCV2).  By May 2010, the FDA recommended that physicians resume 
the use of RV1 and continue use of RV5 since PCV1 and PCV2 are not known to cause 
illness in either pigs or humans.  The labels of both vaccines were updated to disclose the 
presence of PCV viruses.(37)    
     History of rotavirus vaccine recommendations.  The 2006 ACIP recommendations for 
RV5 allowed the first dose to be administered between 6—12 weeks of age with subsequent 
doses administered at 4—10 week intervals so that all three doses could be administered by 
age 32 weeks.(35)  Since RV1 was administered at slightly different ages in clinical trials and 
the ACIP wanted to unify recommendations for the two rotavirus vaccines, the ACIP 
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recommendations changed when RV1 was licensed.  The 2009 ACIP recommendations 
increased the new maximum age at which the first dose could be administered to 14 weeks, 6 
days, and the maximum age at which the last dose could be administered to 8 months, 0 days 
(~35 weeks).  They also eliminated the maximum interval at which a dose could be 
given.(36)   The 2009 ACIP guidelines apply to both RV5 and RV1 and continue to be used 
in practice.  
  
C. Critical review of the literature 
     Predictors of vaccine uptake.  Among eight recommended pediatric vaccines, only the 
hepatitis A vaccine has lower coverage than the rotavirus vaccine in the US (50% versus 
59%).(38)  Not much is known about why newly adopted vaccines like the rotavirus vaccine 
can take years to reach high coverage levels, but individual, provider, and ecologic 
characteristics likely play a role.   At the individual level, parents or guardians may 
consciously choose not to vaccinate their children with any, many, or certain vaccines for 
personal reasons such as the fear of side effects, or the belief that vaccines are not necessary 
to protect child health.(39) Some studies have also shown that children of young mothers 
may also be less likely to be up-to-date on their vaccines than children with older mothers, 
but this finding has been inconsistent across different geographic settings and 
populations.(40-43)  Few studies have specifically examined individual-level predictors of 
rotavirus vaccine uptake.  However, one analysis of 2009 National Immunization Survey 
(NIS) data found that rotavirus and pneumococcus vaccine coverage among black, non-
Hispanic children was lower than coverage among white, non-Hispanic children, even after 
adjusting for poverty status.(44)   Other individual-level predictors inconsistently associated 
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with childhood immunization status include gender, maternal education, birth order, 
interbirth interval, and frequency of emergency room visits.(42, 43, 45-50)   
With regards to provider characteristics, having consistent continuity of care can 
impact the quality of care received, and physician office size, clinic hours, reimbursement 
levels, patient volume, patient education efforts, and geographic location of the office may 
also impact whether a recommended vaccine is administered.(51-62)  The type of physician 
visited may also influence whether an infant receives a rotavirus vaccine.  A national survey 
of physicians in 2007 found that while 85% of pediatricians routinely offered the rotavirus 
vaccine, only 45% of family medicine physicians routinely offered it to eligible patients.(61)  
Other provider, health plan, or health plan utilization characteristics that have been associated 
with the timeliness or completion of recommended childhood vaccines include status of 
provider (private versus public), insurance status of patient (uninsured versus insured), 
number of patient visits to provider, consistency of  medical home, and out-of-pocket 
expenses.(41, 43, 48, 49, 62)    
Geographic characteristics of residence, including the population density, region of 
the country, and population size of the metropolitan statistical area have been important 
predictors of childhood immunization status in some studies, and unimportant in others.(45, 
46, 49, 50, 55, 59) Additional ecologic factors, such as number of physicians per person and 
income level in the area residence, have also been explored.(43, 46)  One study using NIS 
data to measure vaccine coverage among preschool children in four selected medically 
underserved areas found that an area’s need for childhood vaccination interventions was not 
well predicted by a low number of providers per capita, but this finding has not been 
replicated elsewhere.(43)  Another study found that children attending schools in census 
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tracts with low per capita incomes that did not receive first and second doses of DTP and oral 
polio vaccine (OPV) simultaneously were much less likely to be age-appropriately 
vaccinated by age two years compared with children attending schools in census tracts with 
higher per capita incomes that received the first and second doses of DTP and OPV 
simultaneously.(46)   
Timeliness of rotavirus vaccine administration.  Administering the rotavirus vaccines 
at the recommended times (i.e., according to the current ACIP guidelines) is considered 
important because the effectiveness and safety of the vaccines if given before or after the 
recommended time intervals are currently unknown.  However, some studies have argued 
that the allowable administration window should be broadened because the potential number 
of excess deaths from adverse events (i.e., intussusception) would be outnumbered by the 
number of lives saved from diarrheal disease if more infants could receive a rotavirus 
vaccine.(25, 63)   
A recent study using the health insurance claims database, Optuminsight, noted a 
slightly higher level of adherence to the 2009 ACIP guidelines for infants receiving RV1 as 
opposed to RV5.  The authors found that 83.3% of infants receiving RV1 and 76.4% of 
infants receiving RV5 were fully compliant with the ACIP vaccination schedule, and that 
91.0% and 83.4% of infants receiving RV1 and RV5 completed the full vaccine series.(64) 
Rotavirus vaccine effectiveness.  Although the ACIP currently recommends both RV5 
and RV1, RV1 may provide earlier protection than RV5 for fully vaccinated children and 
better overall protection for those receiving only one dose of vaccine because RV1 requires 
only two doses with the last dose given at age four months, while RV5 requires three doses 
with the last dose given at age six months.(65, 66)   However, since the composition and 
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immune response mechanism of RV5 and RV1 differ, such arguments may not be fully 
justified.  Unfortunately, since Phase III clinical trials of RV5 and RV1 used different 
methodologies, including different case definitions, follow-up times, and populations, 
comparative effectiveness analyses of the two rotavirus vaccines cannot be explored using 
clinical trial data.(65)   
     In the general US population, the rotavirus vaccines have been shown to be effective 
at reducing AGE and RGE among a variety of age groups and healthcare settings post-
market.(67-80)  A  study of one-hundred percent hospital discharge data from 18 states 
participating in the Healthcare Cost and Utilization Project (HCUP) in 2007 and 2008 found 
reductions in AGE hospitalizations ranging from 28% to 50% across each of 8 age groups (0-
2, 3-5, 6-11, 12-17, 18-23, 24-35, 36-47, 48-59 months), compared to the annual median rate 
of 101.1 hospitalizations per 10,000 children in the pre-rotavirus vaccine era, 2000-2006.(75)  
Reductions in AGE hospitalizations in age groups not eligible for rotavirus vaccination and 
when such vaccine coverage was low suggested that these vaccines may elicit robust herd 
protection.  Another study using a cohort of commercially insured infants in the MarketScan 
Research Databases in the January-June period of 2008 and 2009 found a relative rate 
reduction of 89% (95% CI, 79 to 94) and 89% (95% CI, 84 to 93)  in RGE hospitalizations 
among vaccinated versus unvaccinated infants.(76, 77)  A case control study conducted at a 
large pediatric hospital in Houston, Texas in 2008 found that three doses of RV5 were 85% 
(95% CI, 55 to 95) and 89% (95% CI,  70 to 96) effective in preventing RGE hospitalizations 
and emergency department visits, and that completion of a partial series offered substantial 
protection.(77)  In the outpatient setting, a study using an insurance claims database found 
that three doses of RV5 were 96% (95% CI, 76 to100) and 28% (95% CI, 22 to 33) effective 
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against RGE-coded and AGE-coded visits from January- May of 2007-2008.(79) Since the 
RV1 vaccine is still relatively new in the U.S., these studies have focused on the 
effectiveness of RV5, or have done so implicitly.   
     Two post-market studies have compared the effectiveness of RV5 and RV1 in the 
same or similar infant populations and found no difference in their effectiveness.   However, 
one study had limited power, the other was an ecologic study, and neither was conducted in 
U.S. infants.(81, 82)  Since herd immunity appears to be an important factor in post-market 
rotavirus vaccine effectiveness studies, effectiveness studies comparing RV5 and RV1 may 
be a challenge in geographic settings that administer both rotavirus vaccines (i.e., US from 
mid-2008 to present). 
 
D. Synopsis or Summary 
     The rotavirus vaccines appear to have been highly effective in preventing RGE and 
AGE healthcare visits during the first few years post-licensure.   Whether such high levels of 
effectiveness can be maintained, how much protection is attributable to direct versus indirect 
(herd) protection, how the effectiveness of RV5 compares to RV1, and how the effectiveness 
of a complete versus partial series compares deserve further exploration.   
     Only two studies have explored predictors of rotavirus vaccination, but since such 
exploration was not the main purpose of either study, a more thorough review of potential 
predictors are needed so targeted interventions can be developed.  The current literature 
suggests that rotavirus vaccine coverage may be lower among non-Hispanic blacks compared 
to non-Hispanic whites and among infants visiting family physicians as opposed to 
pediatricians. 
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CHAPTER II 
STATEMENT OF SPECIFIC AIMS 
 
A.  Specific Aims, Hypotheses, and Rationale 
 
In a population of US privately-insured infants and children, 
 
 
1.  Determine predictors of rotavirus vaccine initiation and completion   
 
Hypothesis. We hypothesize that among ten available predictors, receipt of 
other childhood vaccines (diphtheria, tetanus, and acellular pertussis (DTaP) 
vaccines), the type of physician visited, and geographic size and density of infant 
residence will be the most important predictors of rotavirus vaccine series initiation 
and completion. 
Rationale.  Published studies have identified receipt of other childhood 
vaccines and physician type as important in predicting initiation or completeness of 
either the rotavirus vaccine series or other childhood vaccine series.  We believe that 
parents and providers initiating rotavirus vaccination will generally ensure that the 
infant completes the series since individual and provider motivations and 
circumstances are unlikely to change during the short period of time between doses 
(two months).  Certain geographic settings (rural areas) may be important predictors 
of both rotavirus vaccine series initiation and completion because access to a provider 
or the vaccine may be more difficult in these areas. 
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2. Assess timeliness of rotavirus vaccine administration as per the 2009 Advisory 
Committee on Immunization Practices (ACIP) guidelines 
 Hypothesis. The rotavirus vaccines will generally be administered as per the 
ACIP guidelines, but children vaccinated with monovalent rotavirus vaccine (RV1) 
will be more likely to complete the vaccine series than children vaccinated with 
pentavalent rotavirus vaccine (RV5).  
Rationale.  Since other childhood vaccinations are administered as 
recommended in the majority of populations studied, we expect most infants in our 
privately-insured population to be vaccinated according to the guidelines, especially 
since infants with health insurance may potentially have fewer problems accessing 
the health care system than other infant populations.    However, since RV5 requires 
three doses, but RV1 requires just two doses to complete the series, we hypothesize 
that more infants will complete the RV1 series.     
 
3. Estimate the direct, indirect, total, and overall rotavirus vaccine effectiveness (VE) 
against rotavirus gastroenteritis (RGE) and acute gastroenteritis (AGE) 
hospitalizations among those aged 8 to 20 months over the life course of the vaccines 
Hypothesis.  We hypothesize that the direct VE estimates will remain stable 
over time, but the indirect, total, and overall VE will generally increase.   
Rationale.  We expect herd protection to increase as the percentage of 
rotavirus-vaccinated children in the cohort increase.   Since indirect VE is a measure 
of herd protection, and total and overall VE include measures of herd protection in 
their estimates, we expect these three measures of VE to increase over time.  
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4. Calculate the absolute rate reductions of RGE and AGE hospitalizations attributable 
to the rotavirus vaccine or the rotavirus vaccine program in those aged 8 to 20 months 
Hypothesis. Rate reductions of RGE and AGE hospitalizations will be 
underestimated when only direct or indirect effectiveness is considered.  
Rationale.  Assuming that the direct VE of the rotavirus vaccines in our cohort 
is high (≥90%), accounting for indirect protection will increase the total VE of the 
vaccines only slightly since VE estimates cannot exceed 100%.  However, the 
number of RGE and AGE hospitalizations prevented by indirect protection alone 
could still be large, and failing to account for indirect protection in rotavirus-
vaccinated children could severely underestimate the impact of the rotavirus vaccine.
   
 
 
CHAPTER III 
METHODS 
    
 
A. Overview of Methods 
 
          Creating the various study cohorts required many steps.  We were able to extract 
the outcome variables for both studies and our exposure variable for the VE study 
directly from the MarketScan Research Databases.   However, many exposure variables 
for the patterns of use study and a few covariates for the VE study, including mother’s 
age at infant birth, infant’s primary provider type, and number siblings, had to be 
created using existing variables.  Measurements of rurality required use of US 
Department of Agriculture (USDA) data.  The infant’s date of birth also had to be 
calculated indirectly using birthing codes. Our analysis used standard epidemiologic 
methods (log-risk regression, Cox proportional hazards regression).    
 
B. Design 
 
1. Subject Identification 
 
a. Source Population  
 
          The MarketScan Commercial Claims and Encounters Database 
(“MarketScan Research Databases,” Copyright © Thomson Truven 
Healthcare, Inc) served as the source population for both studies.  Briefly, the 
MarketScan Research Databases link paid health insurance claims and 
encounter data to detailed patient information across sites, types of providers, 
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and over time.(1)   From 2000 to 2010, the size of the database increased from 
approximately 68,000 to 920,000 infants.  Since the infants and children in this 
database all have private insurance, they are not representative of the US 
population; however, they represent a large group of infants that may most 
commonly utilize the rotavirus vaccines.  
 
b. Selection Criteria 
 
          Patterns of Use Analysis.  Infants born in a hospital or outpatient setting 
between January 1, 2006 and September 30, 2010 were identified from the 
MarketScan Research Databases.  We used the International Classification of 
Clinical Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes 
for live born infants, V30-V39, to define the birth date of infants.  If an infant 
had V30-V39 codes on multiple dates, the date of the first code was used as 
the birth date, and those without such codes and corresponding dates were 
excluded.  Infants with birth dates occurring after administration of rotavirus 
vaccines, likely due to coding errors, were excluded.   
          For infants born between January 2006 and February 2010, additional 
eligibility criteria included having at least eleven months of continuous 
enrollment after birth. For infants born between March and September 2010, 
continuous enrollment was defined as enrollment at every month from birth 
until the end of the 2010 calendar year (the end of available data).  In order to 
ensure adequate follow-up time, only infants born before March 2010 were 
included in assessments of vaccine series completion.
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          VE analysis.  Infants with continuous enrollment during infancy, at least 
one outpatient record, and an ICD-9-CM birthing code (V30-V39) between 
May 1, 2000 and April 30, 2005 or May 1, 2006 and April 30, 2010 were 
abstracted from the databases.  Birthing codes identified in mothers’ claims 
were also used to identify birth dates of potentially eligible infants.    If an 
infant or mother had a V30-V39 claim coded on multiple dates, the date of the 
first V30-V39 code was used as the birth date.  Since follow-up for RGE 
began when infants turned eight months and continued until a maximum age of 
20 months, infants receiving doses of rotavirus vaccine after age eight months 
were excluded so that rotavirus vaccine status could be treated as a time-
independent variable. 
  Infants with commercial insurance failing to receive vaccines with 
high coverage rates (≥95%) may have differed from infants receiving such 
vaccines with respect to unmeasured confounding factors, so we required all 
infants in our study to be vaccinated with at least one dose of diphtheria, 
tetanus, and acellular pertussis vaccine (DTaP), using the following Current 
Procedural Terminology (CPT) codes:  90696, 90698, 90700, 90701, 90702, 
90714, 90715, 90718, 90720, 90721, and 90723.  
 
2.  Methods for Proposed Study 
      a.   Classification of Exposure 
     1. Exposure of Interest  
  
          Patterns of Use Analysis.  We identified all potential predictors of 
rotavirus vaccination a priori. Individual level variables included sex, DTaP 
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vaccination status, number of siblings <10 years old, mother’s age at birth, 
and hospitalizations prior to the first dose of rotavirus vaccine or by the 
maximum age at which the first dose of rotavirus vaccine could have been 
administered as per the ACIP guidelines (14 weeks, 6 days).  Variables for 
race and socioeconomic status were not available.    _____ 
Provider and health plan characteristics included the type of physician 
visited during ≥70% of the infant’s outpatient visits (pediatrician, family 
physician, other providers, or no consistent provider type); the network of the 
care received during ≥70% of the infant’s outpatient visits (in-network, or out-
of-network or mixed); and the infant’s type of health plan (basic, 
comprehensive, high-deductible; Exclusive Provider Organization (EPO) or 
Preferred Provider Organization (PPO); Health Maintenance Organization 
(HMO); Point of Service (POS) or POS with capitation ; or Consumer 
Directed Health Plan (CDHP)).  All provider and health plan variables were 
assessed prior to rotavirus vaccination, or fifteen weeks of age if the infant 
was unvaccinated.             
Our ecologic factors of interest were region of the infant’s residence 
(Northeast, Midwest, South, or West) and rurality.  In order to better measure 
rurality, we linked the US Department of Agriculture (USDA), Economic 
Research Service 2003 rural-urban continuum codes to the claims database via 
five-digit Federal Information Processing Standard (FIPS) codes.  The 2003 
rural-urban continuum codes distinguish metropolitan counties by the 
population size of the metropolitan area, and nonmetropolitan counties by the
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population size, degree of urbanization, and adjacency to metropolitan areas.  
These codes classify every US County into either one of three metropolitan 
categories, or one of six nonmetropolitan categories.             
VE Analysis.  RV5 and RV1 vaccination status were identified using 
the Current Procedural Terminology codes (CPT) codes, 90680 and 90681, 
and treated as time-independent.  To increase the specificity of vaccination 
status, we excluded infants living in states with state-funded rotavirus vaccine 
programs (Alaska, Idaho, Massachusetts, Maine, North Dakota, New 
Hampshire, New Mexico, Oregon, Rhode Island, Vermont, Washington, 
Wisconsin, and Wyoming).(2, 3)  
 
     2. Exposure Period  
  
          Patterns of Use Analysis.  All infants meeting the inclusion were 
followed for evidence of rotavirus vaccination until their first birthday or the 
end of the study period (December 31, 2010), whichever came first.  
Predictors were examined and classified during the time period prior to 
administration of the first dose of rotavirus vaccine, or if no doses of rotavirus 
vaccine were administered, the maximum age at which the first dose of 
rotavirus vaccine could have been administered as per the 2009 ACIP 
guidelines (14 weeks, 6 days). 
          VE Analysis.   The exposure, RV5 or RV1, was measured from birth up 
to the maximum age at which rotavirus vaccines are recommended (age 8 
months, 0 days).  Infants receiving a rotavirus vaccine after their 8 month 
birthday were excluded from the study because follow-up of RGE and AGE
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 began at age 8 months, and we chose to treat RV vaccine status as a time-
independent variable.  We followed infants and children from age eight 
months to the age at which they 1) experienced a RGE or AGE 
hospitalization; 2) lost continuous health plan enrollment; 3) reached their 20 
month birthday; 4) reached the end of the study period, whichever happened 
first.   
 Infants and children were allowed to contribute person-time during 
two calendar years.  For example, an infant turning eight months old on 
October 1, 2007, would contribute three person-months in 2007, and then re-
enter the cohort on January 1, 2008 at age 11 months and contribute up to nine 
more calendar months of person-time in 2008.   
 
    3. Measurement Characteristics (reproducibility/validity)  
 
          The MarketScan Research Databases are available for purchase, and the 
details we provided in this dissertation as well as the manuscripts that will be 
submitted to peer-reviewed journals should allow our study to be reproduced 
by other researchers.   
          Internal validation was not possible because the MarketScan Research 
Databases are de-identified.  To our knowledge, the exposures, outcomes, and 
covariates used in this study have not been validated by Thomson Truven 
Healthcare, Inc, the owners of the MarketScan Research Databases.    
However, these databases have fairly comprehensive coding.  For example, 
diagnosis codes are found in 99% of all claims, procedure codes are found on
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85% of physician claims and 100% of the claims are fully paid and 
adjudicated. (4)   In the future, we plan to externally validate rotavirus 
vaccination status and RGE using the North Carolina Immunization Registry 
(NCIR) and the North Carolina Disease Event Tracking and Epidemiologic 
Research Tool (NC DETECT).   
 
       b.  Classification of Outcome  
 
          Patterns of Use Analysis.  For this analysis, our outcome was the 
exposure (rotavirus vaccination status) described for the VE analysis in 
Chapter III, Section 2a.   
          VE Analysis.  Outcomes of RGE were identified using ICD-9-CM 
codes.  Any of the 15 coding fields in the inpatient files of the databases was 
used to capture the ICD-9-CM code for rotavirus-specific disease, 008.61 
Since rotavirus-coded events underestimate the true burden of rotavirus 
disease due to lack of routine laboratory testing and coding, we performed 
sensitivity analyses, assuming 25% and 50% sensitivity of the 008.61 code, 
and also abstracted and examined outcomes related to the following acute 
gastroenteritis (AGE) ICD-9-CM codes:  bacterial (001-005, excluding 003.2, 
and also including 008.0-008.5), parasitic (006-007, excluding 006.3-006.6), 
and viral diarrhea (008.6 and 008.8); diarrhea of undetermined etiology 
(presumed infectious [009.0-009.3] and presumed noninfectious [558.9]); and 
diarrhea not otherwise specified  (787.91). (6-9)    
 
3. Data Analysis 
          For both studies, data were analyzed in SAS, version, 9.2 (SAS Institute, Inc). 
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           Patterns of Use Analysis.  We calculated simple frequencies, and performed 
bivariate and multivariable regression analyses using log-risk models that were 
limited to individual, provider, and ecological characteristics thought to be associated 
with receipt of at least one dose of rotavirus vaccine, and identifiable in the available 
data.    We also used the same potential individual, provider, and ecological 
characteristics to explore predictors of rotavirus vaccine series completion.  In order 
to examine whether predictors of rotavirus vaccination changed over time, we 
repeated the above analyses, restricting the cohort to infants born in 2006 and then 
2009.  Infants with missing data on any potential predictors were excluded from both 
of these analyses. 
          VE Analysis.  We used Cox proportional hazard regression models to calculate 
hazard rate ratios, comparing the hazard of RGE or AGE hospitalization among 
vaccinated infants to unvaccinated infants entering the cohort in 2007, 2008, 2009, or 
2010 and subtracting the result from one to obtain direct VE estimates by calendar 
year.  We similarly calculated the indirect, total, and overall VE, varying the 
comparison cohorts as appropriate.  For indirect VE, we compared unvaccinated 
infants followed during each calendar year of the rotavirus vaccine period, 2007-
2010, to (unvaccinated) infants followed during the baseline period, 2001-2005.  For 
total VE, we compared vaccinated infants followed during each calendar year of the 
rotavirus vaccine period to (unvaccinated) infants followed during the baseline 
period.  For overall or average VE, we compared all vaccinated and unvaccinated 
infants during each calendar year of the rotavirus vaccine period to (unvaccinated) 
infants followed during the baseline period.  Results were stratified by year to account
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 for increasing vaccination coverage and adjusted for month of birth to account for the 
seasonality of rotavirus virus.   
          Incidence rate differences based on the case count and person-years in our 
population, and additional analyses assuming 25% and 50% sensitivity and 100% 
specificity of the RGE and AGE ICD-9-CM codes were calculated to determine the 
absolute number of RGE and AGE hospitalizations prevented by the rotavirus 
vaccine program in our cohort. 
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CHAPTER IV 
RESULTS 
 
A. Patterns of rotavirus vaccine uptake and use in privately-insured US infants, 2006-
2010 
 
1.   Introduction  
Rotavirus gastroenteritis is a leading cause of hospitalizations and emergency 
department visits among young children in the US.(1)  The recently licensed rotavirus 
vaccines, RotaTeq® (Rotavirus Vaccine, live, oral, pentavalent) [RV5] (Merck & 
Co., Inc.) and Rotarix® (Rotavirus Vaccine, live, oral, monovalent) [RV1] 
(GlaxoSmithKline Biologicals), have dramatically reduced incidence of healthcare 
utilization for rotavirus infection.(2) These vaccines are now recommended for 
routine use among US infants by the Advisory Committee on Immunization Practices 
(ACIP).(3, 4)  
Despite these recommendations, the Centers for Disease Control and 
Prevention (CDC) estimated that only 67% of eligible children 19-35 months in the 
US had completed a rotavirus vaccine series in 2011.(5)  Among nine recommended 
pediatric vaccines assessed by the National Immunization Survey (NIS) in 2011, only 
the hepatitis A vaccine had lower coverage than the rotavirus vaccine in the US.(5)   
Little is known about why it can take several years or more for newly recommended 
vaccines like the rotavirus vaccine to reach high coverage levels, but studies to-date
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 suggest that type of physician visited, geographic residence, socio-economic status, 
and race may be important predictors.(5-8)  Considering that the US Department of 
Health and Human Services (HHS) Healthy People 2020 objectives include 
vaccinating at least 80% of children with two or more doses of rotavirus vaccine by 
2020, further exploration regarding the determinants of rotavirus vaccine uptake is 
warranted.(9)   
Using data from a large population of infants with commercial insurance, we 
study patterns of use of rotavirus vaccine.  We examine individual, provider, and 
ecologic correlates of rotavirus vaccine use and vaccine series completion.  We 
hypothesize that receipt of other childhood vaccines (e.g., diphtheria, tetanus, and 
acellular pertussis (DTaP) vaccines) and the type of physician visited will be the most 
important predictors of rotavirus vaccine series initiation and completion.  Our study 
further examines time trends and timeliness of rotavirus vaccine administration as per 
the 2009 ACIP recommendations. 
2. Methods   
 
Infants born in a hospital or outpatient setting between January 1, 2006 and 
September 30, 2010 were identified from the MarketScan Research Databases 
(Copyright © Thomson Truven Healthcare, Inc).  We used the International 
Classification of Clinical Diseases, Ninth Revision, Clinical Modification (ICD-9-
CM) codes for live born infants, V30-V39, to define the birth date of infants.  If an 
infant had V30-V39 codes on multiple dates, the date of the first code was used as the 
birth date, and those without such codes and corresponding dates were excluded. 
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 Infants with birth dates occurring after administration of rotavirus vaccines, likely 
due to coding errors, were excluded.   
For infants born between January 2006 and February 2010, additional 
eligibility criteria included having at least eleven months of continuous enrollment 
after birth. For infants born between March and September 2010, continuous 
enrollment was defined as enrollment at every month from birth until the end of the 
2010 calendar year (the end of available data).  In order to ensure adequate follow-up 
time, only infants born before March 2010 were included in assessments of vaccine 
series completion. 
RV5 and RV1 vaccination status was assessed using the Current Procedural 
Terminology (CPT) codes, 90680 and 90681.  We required infants to have at least 
one outpatient claim because we thought it was important for our cohort to include 
only infants that utilized the healthcare system through their private insurance plan to 
reduce potential misclassification of rotavirus vaccination status.    To further reduce 
exposure misclassification, we excluded infants residing in 13 states with state-
funded vaccine programs (Alaska, Idaho, Massachusetts, Maine, North Dakota, New 
Hampshire, New Mexico, Oregon, Rhode Island, Vermont, Washington, Wisconsin, 
and Wyoming) except for the cohort of infants used to examine adherence to the 
recommended vaccine schedule.(2)  
We used the 2009 ACIP recommendations to assess adherence to the 
recommended rotavirus vaccine schedule for all calendar years, 2006-2010.  If the 
first dose of rotavirus vaccine was given before the age of six weeks, zero days or 
after the age of fourteen weeks, six days, then the recommendations were not met.
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We also considered recommendations to have been violated if any dose was 
given after the age of eight months, zero days, or if the minimum interval between 
two doses was less than four weeks. 
We calculated simple frequencies, and performed bivariate and multivariable 
regression analyses using log-risk models that were limited to individual, provider, 
and ecological characteristics thought to be associated with receipt of at least one 
dose of rotavirus vaccine, and identifiable in the available data.    We also used the 
same potential individual, provider, and ecological characteristics to explore 
predictors of rotavirus vaccine series completion.  In order to examine whether 
predictors of rotavirus vaccination changed over time, we repeated the above 
analyses, restricting the cohort to infants born in 2006 and then 2009.  Infants with 
missing data on any potential predictors were excluded from both of these analyses. 
We identified all potential predictors of rotavirus vaccination a priori. 
Individual level variables included sex, DTaP vaccination status, number of siblings 
<10 years old, mother’s age at birth, and hospitalizations prior to the first dose of 
rotavirus vaccine or by the maximum age at which the first dose of rotavirus vaccine 
could have been administered as per the ACIP guidelines (14 weeks, 6 days).  
Variables for race and socioeconomic status were not available. Provider and health 
plan characteristics included the type of physician visited during ≥70% of the infant’s 
outpatient visits (pediatrician, family physician, other providers, or no consistent 
provider type); the network of the care received during ≥70% of the infant’s 
outpatient visits (in-network, or out-of-network or mixed); and the infant’s type of 
health plan (basic, comprehensive, high-deductible; Exclusive Provider Organization
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 (EPO) or Preferred Provider Organization (PPO); Health Maintenance Organization 
(HMO); Point of Service (POS) or POS with capitation; or Consumer Directed Health 
Plan (CDHP)).  All provider and health plan variables were assessed prior to rotavirus 
vaccination, or fifteen weeks of age if the infant was unvaccinated.  Our ecologic 
factors of interest were region of the infant’s residence (Northeast, Midwest, South, 
or West) and rurality.  In order to better measure rurality, we linked the US 
Department of Agriculture (USDA), Economic Research Service 2003 rural-urban 
continuum codes to the claims database via five-digit Federal Information Processing 
Standard (FIPS) codes.  The 2003 rural-urban continuum codes distinguish 
metropolitan counties by the population size of the metropolitan area, and 
nonmetropolitan counties by the population size, degree of urbanization, and 
adjacency to metropolitan areas.  These codes classify every US County into either 
one of three metropolitan categories, or one of six nonmetropolitan categories.   
All data were managed and analyzed in SAS, version 9.2 (SAS Institute, Cary, 
NC).  This study was considered exempt from human subjects review by the 
institutional review board at the University of North Carolina.   
3. Results 
 
Infant cohorts.  Approximately half (51%) of 2.80 million infants identified in the 
enrollment files between January 2006 and December 2010 had an identifiable ICD-9 
birthing code and corresponding date of service (Figure 3).   Infants that were 
excluded due to missing data generally lacked information on their mother’s age at 
birth.   After additional exclusions, our final cohorts to assess
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predictors of rotavirus vaccine initiation and completion included 594,117 and 
324,264 infants, respectively.    
Temporal trends of rotavirus vaccine uptake.  Rotavirus vaccine uptake among 
infants in our cohort increased from 0% when RV5 was licensed (February 2006) to 
25% when the first ACIP recommendations were published (August 2006) (Figure 1).  
Rotavirus vaccine uptake then increased even more rapidly, doubling to 49% by 
December 2006.  The percentage of infants receiving at least one dose of rotavirus 
vaccine continued to grow steadily, reaching 62% by April 2007 and reaching 70% 
beginning November 2007.    Throughout 2009 and 2010, a median of 81% (range, 
78%-83%) of eligible infants were vaccinated with at least one dose of rotavirus 
vaccine each month.  Among the infants receiving a rotavirus vaccine during our 
study period, 92% received RV5, 5% received RV1, and 3% received a combination 
of the two vaccines. 
Adherence to the 2009 ACIP recommendations.  The median and inter-
quartile range of ages at which infants received doses of rotavirus vaccine followed 
the 2009 ACIP guidelines of two, four, and six months of age (Table 1).  Almost all 
infants received their rotavirus vaccines between the minimum (6 weeks) and 
maximum (8 months, 0 days) recommended ages, and received dose one and dose 
two at least four weeks apart.  Although the 2009 ACIP guidelines do not specify a 
maximum interval in which two doses should be given, 18% of infants received a 
second dose of rotavirus vaccine more than 10 weeks after their first dose, and 7% of 
infants received their second dose more than 12 weeks after their first dose.  Across 
all years, approximately 8% of infants received their first dose of rotavirus vaccine at
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ages older than the maximum recommended age for the first dose (14 weeks, 6 days), 
with 19% of infants in 2006 and 6.0-8.5% of infants from 2007 to 2010, receiving 
their first dose after age 14 weeks, 6 days.    Although most infants who initiated 
rotavirus vaccination completed the full series, more infants completed the series for 
RV1 than RV5 or a combination of the two vaccines (87% versus 79% versus 73%, 
P<0.001). 
Univariate, bivariate and multivariable analyses.  Among 594,117 infants, 
69% received at least one dose of rotavirus vaccine between February 2006 and 
December 2010 (Table 2).  Most infants in the cohort were also vaccinated with at 
least one dose of DTaP, were born to mothers 25-39 years of age, were first born 
children or had one older sibling, visited in-network physicians, were enrolled in EPO 
or PPO health plans, received outpatient care from pediatricians, resided in the 
Midwest or South, and lived in large metropolitan areas.   
The strongest predictors of rotavirus vaccine initiation among infants born 
January 2006-September 2010 were receipt of DTaP (bivariate:  RR= 7.91, 95% CI= 
7.69-8.13; multivariable:  RR= 7.50, 95% CI= 7.30-7.71), and visiting a pediatrician 
versus family physician for routine care (bivariate:  RR= 1.64, 95% CI= 1.63-1.66; 
multivariable:  RR=1.51, 95% CI=1.49-1.52).  Infants were slightly less likely to 
receive a rotavirus vaccine if they lived in the Northeast as opposed to the South, or 
in a small urban or rural area as opposed to a large metropolitan area. As the number 
of siblings less than 10 years of age in the household increased, infants became less 
likely to receive a rotavirus vaccine. 
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In order to determine whether predictors of rotavirus vaccine initiation 
changed over time, we also examined predictors of infants born when RV5 was first 
licensed (2006) with those born three years after RV5 licensure (2009).  Compared to 
the 2006 birth cohort, visiting a pediatrician versus a family physician in the 2009 
birth cohort was a less important predictor of rotavirus vaccine initiation (2006:  
RR=2.15, 95% CI= 2.02-2.28; 2009:  RR=1.35, 95% CI = 1.32-1.37) as was residing 
in a metropolitan area with less than one million population versus an area with at 
least one million population.   
Family physicians often provide care more frequently in rural areas, and 
infants visiting family physicians or residing in rural areas were independently less 
likely to receive a dose of rotavirus vaccine. We therefore explored potential 
interactions between the type of physician visited (pediatrician versus family 
physician) for routine care and population size of residence (metropolitan areas 
versus non-metropolitan areas), but did not find an interaction in these post-hoc 
analyses (Figure 2).   
The most important predictors of rotavirus vaccine series completion were receipt 
of DTaP and receiving routine care from a pediatrician as opposed to a family 
physician. The strength of the associations in multivariable analyses were 6-fold and 
1.3-fold smaller than in the multivariable analyses of rotavirus vaccine initiation, and 
the strength of the association decreased from 2006 to 2009 (Table 3).  Infants born to 
younger mothers (<25 years) and with more siblings were slightly less likely to 
complete the rotavirus vaccine series, and this trend remained consistent in 2006 and 
2009. Infants residing outside of metropolitan areas were generally less likely to
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complete the rotavirus vaccine series.  Region of residence was not an important 
predictor of vaccine series completion.
4. Discussion 
 
We observed rapid diffusion of the rotavirus vaccine into routine practice shortly 
after licensure in the US.  Approximately three quarters of infants born from early 
2008 through mid-2010, received two or more doses.  This estimate is slightly higher 
than the CDC estimate that analyzed data for infants born during approximately the 
same time period using a population-based telephone survey (NIS), and 5% lower 
than the HHS’ Healthy People 2020 goal.(5, 9)  Our estimate may be higher than the 
CDC estimate and  may have overestimated the progress towards the Healthy People 
2020 goal for several reasons.  First, our population included only infants with 
commercial insurance who may be more likely to be vaccinated than other infant 
populations, such as the uninsured or those with Medicaid insurance.  Second, our 
cohort consisted of a non-population based sample of infants.   Since the MarketScan 
Research Databases have increased in size over time, our data were weighted towards 
the later years (e.g., 2010) when rotavirus vaccine coverage was relatively high 
compared to the earlier years.  In addition, infants residing in rural and small urban 
areas were less likely to be vaccinated in our study, but also underrepresented.       
It was surprising that one-quarter of eligible infants received at least one dose 
of rotavirus vaccine prior to the publication of the first ACIP recommendations in 
August 2006.  This reflects the importance of other communication networks and the 
apparent readiness of the manufacturer, insurance companies, and providers to deliver 
the rotavirus vaccine.  Despite the initial rapid uptake of the rotavirus vaccine, 
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approximately one-fifth of infants were still not receiving the vaccine in January 2009 
and coverage has failed to further increase since this time.  Education interventions,
particularly those targeted at family physicians should be considered.  This 
recommendation is consistent with the results of a 2007 nationally-representative 
survey of pediatricians and family physicians which found that pediatricians were 
much more likely to administer the rotavirus vaccine to eligible infants than family 
physicians, possibly because family physicians were more concerned with vaccine 
safety and adding additional vaccines to the childhood schedule than pediatricians.(8) 
Studies examining other vaccines in various populations of infants and young 
children have also shown that family physicians may be less likely to adopt and may 
be less knowledgeable about vaccine recommendations than pediatricians.(10)  
Since most children who received a rotavirus also received at least one other 
recommended childhood vaccine (e.g., DTaP), it appears that neither parents nor 
providers are “cherry-picking” vaccines.  Rather, it appears that infants either 
generally receive the recommended childhood vaccines or do not.  This observation is 
further supported by a post-hoc analysis that found a high correlation between the 
number of doses of DTaP (one, two, or three) and number of doses of RV5 (one, two, 
or three) received among infants in our cohort (r=0.76).   Since our cohort consisted 
of infants with private insurance who had at least one outpatient record, failure to 
access the healthcare system cannot fully explain why some infants did not receive 
recommended vaccines, such as DTaP or rotavirus.  Based on our results, 
interventions aimed at increasing the coverage of any one childhood vaccine may 
help increase the coverage and timeliness of other recommended childhood vaccines, 
   
41 
 
assuming that vaccine availability is not an issue.  This was shown to be the case for 
the DTaP vaccine in Australia, where the third dose coverage of DTaP vaccine in a
pre-RV5 cohort was 80%, but increased by 5 to 12 percent once the RV5 vaccine was 
available and widely used.(11)     
Overall, adherence to the 2009 ACIP guidelines for rotavirus vaccine 
administration was high.  Although we compared all years of data (2006 to 2010) to 
the 2009 ACIP guidelines which are less stringent than the 2006 ACIP guidelines, 
adherence remained high even when we reanalyzed our data using the 2006 ACIP 
guidelines (data not shown).  Despite overall high levels of compliance to the 2009 
ACIP recommendations, ensuring that infants complete the rotavirus vaccine series 
could be improved.  Other multi-dose vaccines face a similar challenge.  Prior to 
rotavirus vaccine availability, the vaccination histories of over 17,000 children in the 
2005 NIS were reviewed, revealing that of the 28% of children not compliant with 
ACIP recommendations, two-thirds were categorized as such because they were 
missing doses for multi-dose vaccinations.(12)  However, since vaccination coverage 
has been shown to increase as the number of physician office visits increase, one 
remedy physicians could consider is vaccinating infants at-risk for missing office 
visits with RV1 since it requires only two doses to complete the series.(13)  However, 
since identifying infants at-risk for missing office visits can be difficult, this 
recommendation may only be practical in theory.  Furthermore, post-marketing data 
comparing partial series effectiveness of RV5 to RV1 are limited.(14)  
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            Our analyses are subject to limitations.  Many variables potentially 
predictive of rotavirus vaccine uptake were not available in our data.  Further 
research is needed to examine the effect of potentially relevant predictors, such as 
race, ethnicity, family economic status, and physician reimbursement levels. We 
were unable to validate important estimated dates, such as birth dates and 
rotavirus vaccination dates.  While such misclassifications could affect the results 
of our analysis that assesses adherence to the 2009 ACIP recommendations, we 
do not suspect that there was enough misclassification to affect our overall 
conclusions and they are consistent with the results from another recently 
published study.(15)  As mentioned earlier in the discussion, the infants in our 
cohorts were not representative of the US infant population; however, our study 
included nearly 600,000 infants with commercial insurance who may represent 
the group of infants that most commonly utilizes the rotavirus vaccines.       
           Our study revealed rapid initial uptake of the vaccine after RV5 was first 
licensed.  However, even several years after licensure, many children still did not 
receive the vaccine or received an incomplete series.  Quality improvement efforts 
should focus on ensuring that (1) infants complete the two-dose series for RV1 
and three-dose series for RV5 or a mixed series; (2) family physicians receive the 
adequate education and support necessary to increase the rates of vaccination 
among infants in their care; and (3) other recommended infant vaccinations are 
administered. 
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5.  Figures and Tables 
 
FIGURE 1.  Percent and number of infants vaccinated with at least one dose of 
rotavirus vaccine, February 2006-November 2010 (n=825,300) 
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TABLE 1.  Adherence to the rotavirus vaccination 2009 ACIP Guidelines 
 (n=486,295)1 
Variable  Number (%) 
Median age in days (IQR)    
     Dose 1 63 (61-69) 
     Dose 2 126 (123-135) 
     Dose 3 (RV5 only) 188 (184-197) 
RV5, number of doses received in series    
     One (incomplete) 30,256  (6.8) 
     Two (incomplete) 63,294  (14.2) 
     Three (complete) 349,599  (78.4) 
     Four or more (too many doses) 2589 (0.6) 
RV1, number of doses received in series    
     One (incomplete) 3509  (13.5) 
     Two (complete) 21,588  (83.3) 
     Three or more (too many doses) 823 (3.2) 
Mixed series    
     Incomplete 3933  (26.9) 
     Complete 9819  (67.1) 
     Complete (too many doses) 885 (6.1) 
Administered first dose too early 
 (<6 weeks) 
  
 
     No  484,979  (99.7) 
        Yes  1316  (0.3) 
Administered first dose too late 
(>14 weeks, 6 days) 
  
        No 447,442  (92.0) 
      Yes 39,557  (8.0) 
Administered any dose too late 
 (>8 months, 0 days)  
  
      No 476,647  (98.0) 
      Yes 9648  (2.0) 
Minimum interval between first two doses 
violated (<4 weeks) 
  
      No 450,922  (99.6) 
      Yes 1608  (0.4) 
1Infants vaccinated with RV5, RV1, or a mixed series and enrolled ≥11months.   
 Abbreviations:  ACIP, Advisory Committee on Immunization Practices; IQR, 
 interquartile range; RV1, monovalent rotavirus vaccine; RV5, pentavalent 
 rotavirus vaccine
   
   
  
4
5
 
TABLE 2.  Estimates of rotavirus vaccine receipt, one or more doses (n=594,117) 
Variable No. infants 
receiving ≥1 dose 
of RV5 or RV1 
in category, born 
2006-2010 (%) 
Bivariate RR, 
born 2006-2010  
(95% CI) 
 
Multivariable 
RR, born 2006-
2010 
(95% CI) 
Multivariable 
RR, born 2006 
(95% CI) 
 
Multivariable 
RR, born 2009 
(95% CI) 
Overall  409,557 (68.9) --- --- --- --- 
Sex      
     Female 200,442 (69.0) Ref Ref. Ref. Ref. 
     Male 209,115 (68.9) 1.00 (1.00-1.00) 1.00 (1.00-1.00) 1.00 (0.98-1.02) 1.00 (1.00-1.00) 
DTaP vaccination       
     No 4645   (9.4) Ref Ref. Ref. Ref. 
     Yes 404,912 (74.3) 7.91 (7.69-8.13) 7.50 (7.30-7.71) 7.28 (6.59-8.04) 6.95 (6.57-7.34) 
Hospitalized      
     No 397,832 (69.1) Ref Ref. Ref. Ref. 
     Yes 11,725 (64.3) 0.93 (0.92-0.94) 0.96 (0.95-0.97) 1.05 (1.00-1.10) 0.99 (0.98-1.00) 
Number of siblings <10 years      
      0 187,647 (71.2) Ref Ref. Ref. Ref. 
      1 156,922 (68.7) 0.96 (0.96-0.97) 0.97 (0.97-0.97) 0.96 (0.94-0.98) 0.99 (0.98-0.99) 
      2 52,803 (64.9) 0.91 (0.91-0.92) 0.94 (0.94-0.94) 0.95 (0.92-0.97) 0.97 (0.96-0.97) 
      3 or more 12,185 (58.3) 0.81 (0.81-0.83) 0.89 (0.88-0.90) 0.91 (0.86-0.96) 0.90 (0.88-0.91) 
Mother’s age (years)      
     <25  36,376 (63.7) 0.91 (0.90-0.91) 0.95 (0.95-0.96) 0.96 (0.93-0.99) 0.99 (0.98-1.00) 
     25-<30 130,089 (68.9) 0.98 (0.97-0.98) 0.99 (0.99-0.99) 0.98 (0.96-1.00) 1.00 (1.00-1.00) 
     30-<35 152,610 (70.4) Ref Ref. Ref. Ref. 
     35-40 75,185 (69.2) 0.98 (0.98-0.99) 0.99 (0.98-0.99) 1.02 (0.99-1.05) 0.99 (0.99-1.00) 
     ≥40 15,297 (67.5) 0.96 (0.95-0.97) 0.97 (0.97-0.98) 0.95 (0.90-1.00) 0.98 (0.97-0.99) 
Primary provider type      
     Pediatrician 266,740 (75.8) 1.64 (1.63-1.66) 1.51 (1.49-1.52) 2.15 (2.02-2.28) 1.35 (1.32-1.37) 
     Family physician 15,790 (46.1) Ref. Ref. Ref. Ref. 
   
   
  
4
6
 
     Other providers 75,312 (61.3) 1.33 (1.31-1.34) 1.31 (1.29-1.32) 1.77 (1.66-1.88) 1.27 (1.25-1.30) 
     No consistent provider type 51,715 (60.6) 1.31 (1.30-1.33) 1.30 (1.28-1.32) 1.53 (1.43-1.64) 1.23 (1.21-1.26) 
Network of provider type      
     In-network  368,525 (69.4) 1.07 (1.07-1.08) 1.00 (1.00-1.00) 0.91 (0.88-0.94) 0.99 (0.98-1.00) 
     Out of network or mix of  
       networks 
41,032 (64.7) Ref. Ref. Ref. Ref. 
Health plan type       
     Basic, comprehensive, or high  
___deductible  
7597 (68.0) 0.99 (0.98-1.01) 1.02 (1.01-1.03) 0.76 (0.70-0.83) 1.01 (0.99-1.03) 
     EPO or PPO 293,141 (68.6) Ref. Ref. Ref. Ref. 
     HMO 59,901 (70.5) 1.03 (1.02-1.03) 0.99 (0.98-0.99) 0.90 (0.88-0.93) 1.00 (0.99-1.01) 
     POS or POS with capitation 36,495 (68.5) 1.00 (0.99-1.01) 0.97 (0.96-0.97) 0.98 (0.95-1.01) 1.00 (0.99-1.01) 
     CDHP 12,423 (72.9) 1.06 (1.05-1.07) 1.03 (1.02-1.04) 0.95 (0.90-1.01) 1.01 (0.99-1.01) 
Region of residence      
     Northeast 48,468 (68.2) 0.96 (0.95-0.96) 0.92 (0.92-0.93) 0.73 (0.70-0.76) 0.89 (0.89-0.90) 
     Midwest 122,396 (66.0) 0.93 (0.92-0.93) 0.98 (0.98-0.98) 0.94 (0.92-0.96) 1.01 (1.01-1.02) 
     South 202,587 (71.3) Ref. Ref. Ref. Ref. 
     West 36,106 (67.9) 0.95 (0.95-0.96) 0.97 (0.97-0.98) 0.72 (0.69-0.76) 0.97 (0.96-0.98) 
Type of residence      
     Metro with ≥1 M pop 250,066 (71.2) Ref. Ref. Ref. Ref. 
     Metro with 250,000 – 1 M pop 74,009 (70.3) 0.99 (0.98-0.99) 1.04 (1.03-1.04) 1.16 (1.13-1.19) 1.02 (1.01-1.02) 
     Metro with <250,000 pop  39,238 (67.8) 0.95 (0.95-0.96) 1.01 (1.00-1.02) 1.20 (1.16-1.23) 1.00 (0.99-1.01) 
     Urban with ≥20,000 pop, 
___adjacent to metro area 
13,445 (61.9) 0.87 (0.86-0.88) 0.98(0.97-0.99)( 1.02 (0.97-1.07) 0.98 (0.96-0.99) 
     Urban with ≥20,000 pop, 
       not adjacent to metro area 
6348 (56.8) 0.80 (0.78-0.81) 0.93 (0.92-0.94) 0.99 (0.92-1.06) 0.96 (0.94-0.98) 
     Urban with 2500-19,999 pop,   
___adjacent to metro area 
15,416 (58.5) 0.82 (0.81-0.83) 
 
0.96 (0.95-0.97) 0.95 (0.91-1.00) 0.96 (0.94-0.97) 
     Urban with 2500-19,999 pop, 
___not adjacent to metro area 
7048 (50.5) 0.71 (0.70-0.72) 0.90 (0.89-0.92) 0.91 (0.84-0.97) 0.94 (0.92-0.96) 
     Rural or <2500 population, 
___adjacent to metro area 
2146 (63.7) 0.89 (0.87-0.92) 0.99 (0.97-1.01) 1.01 (0.90-1.15) 0.99 (0.96-1.02) 
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     Rural or <2500 population,  
      not adjacent to metro area 
1841 (56.1) 0.79 (0.76-0.81) 0.98 (0.95-1.00) 1.04 (0.90-1.20) 0.94 (0.90-0.98) 
Abbreviations: CDHP, Consumer Directed Health Plan; DTaP, diphtheria, tetanus, and acellular pertussis; EPO, Exclusive Provider 
Organization; HMO, Health Maintenance Organization; Metro, metropolitan; Pop, population; POS, Point of Service; PPO, Preferred 
Provider Organization; RV1, monovalent rotavirus vaccine; RV5, pentavalent rotavirus vaccine 
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FIGURE 2. Percent of infants vaccinated with at least one dose of rotavirus vaccine, 
February 2006-November 2010 by physician type and geographic area1 (n=385,291) 
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TABLE 3.  Estimates of rotavirus vaccine series completion (n=324,264) 
Variable No. infants 
receiving ≥1 dose 
of RV5 or RV1 
in category, born 
2006-2010 (%) 
Bivariate RR, 
born 2006-2010  
(95% CI) 
 
Multivariable 
RR, born 2006-
2010 
(95% CI) 
Multivariable 
RR, born 2006 
(95% CI) 
 
Multivariable 
RR, born 2009 
(95% CI) 
Overall  259,701 (80.1) --- --- --- --- 
Sex      
     Female 127,460 (80.3) Ref. Ref. Ref. Ref. 
     Male 132,241 (79.9) 1.00 (0.99-1.00) 1.00 (0.99-1.00) 0.98 (0.97-1.00) 1.00 (0.99-1.00) 
DTaP vaccination       
     No 2502 (62.6) Ref. Ref. Ref. Ref. 
     Yes 257,199 (80.3) 1.28 (1.25-1.31) 1.26 (1.23-1.29) 1.47 (1.32-1.63) 1.24 (1.19-1.29) 
Hospitalized      
     No 252,144 (80.2) Ref. Ref. Ref. Ref. 
     Yes 7557 (77.3) 0.96 (0.95-0.98) 0.97 (0.96-0.99) 1.00 (0.96-1.04) 0.97 (0.95-0.98) 
Number of siblings <10 years      
      0 120,863 (82.2) Ref. Ref. Ref. Ref. 
      1 99,233 (79.5) 0.97 (0.96-0.97) 0.96 (0.96-0.97) 0.96 (0.95-0.98) 0.97 (0.96-0.98) 
      2 32,500 (76.3) 0.93 (0.92-0.93) 0.92 (0.92-0.93) 0.91 (0.89-0.93) 0.93 (0.92-0.94) 
      3 or more 7105 (72.4) 0.88 (0.87-0.89) 0.88 (0.87-0.89) 0.88 (0.84-0.92) 0.89 (0.87-0.91) 
Mother’s age (years)      
     <25  21,999 (73.9) 0.91 (0.90-0.91) 0.91 (0.91-0.92) 0.91 (0.88-0.93) 0.93 (0.91-0.94) 
     25-<30 81,946 (79.6) 0.98 (0.97-0.98) 0.98 (0.98-0.98) 0.97 (0.95-0.99) 0.98 (0.98-0.99) 
     30-<35 97,386 (81.5) Ref. Ref. Ref. Ref. 
     35-40 48,715 (81.2) 1.00 (0.99-1.00) 1.00 (0.99-1.00) 1.00 (0.98-1.02) 1.00 (0.99-1.01) 
     ≥40 9655 (80.1) 0.98 (0.97-0.99) 0.98 (0.97-0.99) 0.97 (0.93-1.01) 0.98 (0.97-1.00) 
Primary provider type      
     Pediatrician 171,512 (82.0) 1.16 (1.14-1.17) 1.13 (1.11-1.14) 1.23 (1.16-1.31) 1.14 (1.12-1.16) 
     Family physician 8554 (70.9) Ref. Ref. Ref. Ref. 
     Other providers 48,874 (77.4) 1.09 (1.08-1.11) 1.07 (1.06-1.08) 1.17 (1.10-1.24) 1.09 (1.07-1.11) 
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     No consistent provider type 30,761 (77.1) 1.09 (1.07-1.10) 1.07 (1.06-1.08) 1.18 (1.11-1.25) 1.08 (1.06-1.10) 
Network of provider type      
     In-network  234,753 (80.1) 1.01 (1.00-1.01) 1.00 (0.99-1.00) 1.00 (0.97-1.03) 0.97 (0.96-0.99) 
     Out of network or mix of  
       networks 
24,948 (79.9) Ref. Ref. Ref. Ref. 
Health plan type       
     Basic, comprehensive, or high  
___deductible  
3639 (81.0) 1.01 (1.00-1.03) 1.02 (1.00-1.03) 0.98 (0.91-1.04) 1.01 (0.99-1.03) 
     EPO or PPO 183,987 (79.8) Ref. Ref. Ref. Ref. 
     HMO 40,726 (80.9) 1.01 (1.01-1.02) 1.00 (1.00-1.01) 1.02 (1.00-1.04) 0.99 (0.98-1.00) 
     POS or POS with capitation 24,960 (80.2) 1.01 (1.00-1.01) 1.00 (1.00-1.01) 1.02 (1.00-1.05) 0.99 (0.98-1.01) 
     CDHP 6389 (81.2) 1.02 (1.01-1.03) 1.01 (1.00-1.02) 1.04 (0.99-1.08) 1.00 (0.99-1.02) 
Region of residence      
     Northeast 29,415 (80.7) 1.01 (1.01-1.02) 0.99 (0.99-1.00) 1.05 (1.02-1.08) 0.97 (0.96-0.98) 
     Midwest 78,228 (80.8) 1.01 (1.01-1.02) 1.02 (1.02-1.03) 1.01 (1.00-1.03) 1.03 (1.02-1.03) 
     South 131,635 (79.8) Ref. Ref. Ref. Ref. 
     West 20,423 (78.5) 0.98 (0.98-0.99) 0.99 (0.98-0.99) 0.93 (0.90-0.97) 0.99 (0.98-1.00) 
Type of residence      
     Metro with ≥1 M pop 160.617 (81.3) Ref. Ref. Ref. Ref. 
     Metro with 250,000 – 1 M pop 47,204 (81.1) 1.00 (0.99-1.00) 1.01 (1.00-1.01) 1.01 (0.99-1.03) 1.01 (1.00-1.02) 
     Metro with <250,000 pop  24,533 (77.7) 0.96 (0.95-0.96) 0.98 (0.97-0.98) 0.96 (0.94-0.99) 0.98 (0.97-0.99) 
     Urban with ≥20,000 pop, 
___adjacent to metro area 
8095 (76.1) 0.94 (0.93-0.95) 0.96 (0.95-0.97) 0.87 (0.83-0.92) 0.99 (0.97-1.01) 
     Urban with ≥20,000 pop,  
       not adjacent to metro area 
3869 (74.7) 0.92 (0.90-0.93) 0.94 (0.94-0.96) 0.91 (0.86-0.97) 0.95 (0.92-0.97) 
     Urban with 2500-19,999 pop,   
___adjacent to metro area 
9000 (73.5) 0.90 (0.89-0.91) 0.93 (0.92-0.94) 0.91 (0.87-0.95) 0.94 (0.92-0.95) 
     Urban with 2500-19,999 pop, 
       not adjacent to metro area 
3997 (70.0) 0.86 (0.85-0.88) 0.90 (0.88-0.91) 0.84 (0.78-0.90) 0.90 (0.87-0.92) 
     Rural or <2500 population, 
___adjacent to metro area 
1333 (77.3) 0.95 (0.93-0.97) 0.98 (0.95-1.0) 0.94 (0.84-1.04) 0.98 (0.94-1.03) 
     Rural or <2500 population,  1053 (71.7) 0.88 (0.85-0.91) 0.92 (0.89-0.95) 1.03 (0.92-1.15) 0.92 (0.87-0.98) 
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       not adjacent to metro area 
Abbreviations: CDHP, Consumer Directed Health Plan; DTaP, diphtheria, tetanus, and acellular pertussis; EPO, Exclusive Provider 
Organization; HMO, Health Maintenance Organization; Metro, metropolitan; Pop, population; POS, Point of Service; PPO, Preferred 
Provider Organization; RV1, monovalent rotavirus vaccine; RV5, pentavalent rotavirus vaccine
  
FIGURE 3.  Development of study cohorts,
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 MarketScan Research Databases, 2006
 
-2010  
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B. Direct, indirect, total and overall effectiveness of the rotavirus vaccines in preventing 
gastroenteritis hospitalizations in privately-insured US children, 2007-2010 
 
1. Introduction   
 
Most Phase III vaccine efficacy trials focus on determining the direct 
effectiveness of vaccination, generally measured as one minus the relative risk in the 
vaccinated group compared to the unvaccinated group.  Some clinical trials and many 
post-licensure studies also measure herd protection or indirect vaccine effectiveness 
(VE), defined as population-level effects of widespread vaccination on people not 
receiving the vaccine.(1)  Two additional measures of VE, total and overall VE, 
account for both the direct and indirect effectiveness of a vaccine (Figure 4).   Total 
VE combines the direct and indirect VE on individuals receiving the vaccine, while 
the overall VE weights the average of the total VE on individuals receiving the 
vaccine with the indirect VE on individuals not receiving the vaccine.(1)  Total VE 
can thus be interpreted as the complete benefit of vaccination in vaccine recipients 
and overall VE can be interpreted as the public health benefit of vaccination.   Despite 
challenges in estimating the four types of VE, they are essential to understand the 
real-world impact of a vaccine.(16-18)  
We compared direct, indirect, total and overall rotavirus VE estimates in 
preventing rotavirus gastroenteritis (RGE) and acute gastroenteritis (AGE) 
hospitalizations from 2007 to 2010 in a commercially insured population of US 
infants and children 8 to 20 months of age.  We also examined how the absolute 
number of gastroenteritis hospitalizations varied as effectiveness estimates varied 
through the years.  We hypothesized that the direct VE estimates would remain stable
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over time, but the indirect, total, and overall VE estimates which are or include 
measures of  herd protection would increase as the percentage of rotavirus-vaccinated 
children increased over time.  Furthermore, failing to account for herd protection, 
even among the vaccinated, would underestimate the absolute number of 
hospitalizations prevented by the vaccines.  Briefly, the pentavalent rotavirus vaccine 
(RV5), RotaTeq  (Merck & Co., Inc.), administered orally in three doses at ages two, 
four, and six months, has been recommended for routine use among US infants since 
February 2006 and the monovalent rotavirus vaccine (RV1), Rotarix  
(GlaxoSmithKline Biologicals), administered orally in two doses at ages two and four 
months, has been recommended since June 2008 by the Advisory Committee on 
Immunization Practices (ACIP).(19, 20) 
2. Methods 
 
Data Source.  The MarketScan Research Databases contain data from a large 
number of individuals in the US with commercial insurance.  In 2010, the database 
included approximately 920,000 infants.   
Design and Population.  Infants with continuous enrollment during infancy, at 
least one outpatient record, and an International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM) birthing code (V30-V39) between May 
1, 2000 and April 30, 2005 or May 1, 2006 and April 30, 2010 were abstracted from 
the databases.  Birthing codes identified in mothers’ claims were also used to identify 
birth dates of potentially eligible infants.    If an infant or mother had a V30-V39 
claim coded on multiple dates, the date of the first V30-V39 code was used as the 
birth date.  Since follow-up for RGE began when infants turned eight months and 
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continued until a maximum age of 20 months, infants receiving doses of rotavirus 
vaccine after age eight months were excluded so that rotavirus vaccine status could be 
treated as a time-independent variable. 
Infants with commercial insurance failing to receive vaccines with high 
coverage rates (≥95%) may have differed from infants receiving such vaccines with 
respect to unmeasured confounding factors, so we required all infants in our study to 
be vaccinated with at least one dose of diphtheria, tetanus, and acellular pertussis 
vaccine (DTaP), using the following Current Procedural Terminology (CPT) codes:  
90696, 90698, 90700, 90701, 90702, 90714, 90715, 90718, 90720, 90721, and 90723.  
Outcome, Exposure, and Covariate Measurements.  Outcomes of RGE were 
identified using ICD-9-CM codes.  Any of the 15 coding fields in the inpatient files of 
the databases was used to capture the ICD-9-CM code for rotavirus-specific disease, 
008.61.  Since rotavirus-coded events underestimate the true burden of rotavirus 
disease due to lack of routine laboratory testing and coding, we performed sensitivity 
analyses, assuming 25% and 50% sensitivity of the 008.61 code, and also abstracted 
and examined outcomes related to the following acute gastroenteritis (AGE) ICD-9-
CM codes:  bacterial (001-005, excluding 003.2, and also including 008.0-008.5), 
parasitic (006-007, excluding 006.3-006.6), and viral diarrhea (008.6 and 008.8); 
diarrhea of undetermined etiology (presumed infectious [009.0-009.3] and presumed 
noninfectious [558.9]); and diarrhea not otherwise specified  (787.91).(21-25 )  
RV5 and RV1 vaccination status were identified using the CPT codes, 90680 
and 90681, and treated as time-independent.  To increase the specificity of 
vaccination status, we excluded infants living in states with state-funded rotavirus
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vaccine programs (Alaska, Idaho, Massachusetts, Maine, North Dakota, New 
Hampshire, New Mexico, Oregon, Rhode Island, Vermont, Washington, Wisconsin, 
and Wyoming).(25, 26) 
To help account for different levels of exposure to rotavirus due to household 
and geographic variations in rotavirus vaccine coverage, disease, and mixing 
behaviors, we examined the number of other dependents less than 10 years old 
covered by the same insurance holder as the infant (considered “older siblings”), and 
also the region and rurality of the child’s residence, as defined by the US Department 
of Agriculture (USDA), Economic Research Service.(27)  To characterize general 
infant health and potential differences in susceptibility to rotavirus disease, we 
compared the percentage of infants less than two months that had overnight hospital 
stays unrelated to AGE prior to age two months. 
Data Analysis.  We used Cox proportional hazard regression models to 
calculate hazard rate ratios, comparing the hazard of RGE or AGE hospitalization 
among vaccinated infants to unvaccinated infants entering the cohort in 2007, 2008, 
2009, or 2010 and subtracting the result from one to obtain direct VE estimates by 
calendar year.  We similarly calculated the indirect, total, and overall VE, varying the 
comparison cohorts as appropriate.  For indirect VE, we compared unvaccinated 
infants followed during each calendar year of the rotavirus vaccine period, 2007-
2010, to (unvaccinated) infants followed during the baseline period, 2001-2005.  For 
total VE, we compared vaccinated infants followed during each calendar year of the 
rotavirus vaccine period to (unvaccinated) infants followed during the baseline 
period.  For overall or average VE, we compared all vaccinated and unvaccinated 
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infants during each calendar year of the rotavirus vaccine period to (unvaccinated) 
infants followed during the baseline period.     
In all regression analyses, age served as the underlying time variable, and 
infants were censored when they experienced a RGE or AGE hospitalization, lost 
continuous enrollment, reached their 20 month birthday, or reached the end of the 
study period on December 31, 2010, whichever occurred first.  Results were stratified 
by year to account for increasing vaccination coverage and adjusted for month of 
birth to account for the seasonality of rotavirus.  Infants and children were allowed to 
contribute person-time during two calendar years.  For example, an infant turning 
eight months old on October 1, 2007, would contribute three person-months in 2007, 
and then re-enter the cohort on January 1, 2008 at age 11 months and contribute up to 
nine more calendar months of person-time in 2008.   
Incidence rate differences based on the case count and person-years in our 
population, and additional analyses assuming 25% and 50% sensitivity and 100% 
specificity of the RGE and AGE ICD-9-CM codes were calculated to determine the 
absolute number of RGE and AGE hospitalizations prevented by the rotavirus 
vaccine program in our cohort. 
All analyses were conducted in SAS, version, 9.2 (SAS Institute, Inc).  This 
study was exempt from human subjects review by the Institutional Review Board at 
the University of North Carolina since only deidentified data were used.  
 
3. Results 
 
Cohort.  Approximately half (52%) of the 3.94 million infants identified in the 
enrollment files between January 2000 and December 2010 had an ICD-9 birthing
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code (V30-39) with a date of service in the infant or mothers’  inpatient or outpatient 
claims (Figure 5).  After additional exclusions, among the 905,718 children in our 
final cohort, 627,818 (78%) were born during the rotavirus vaccination period, May 
2006-April 2010 (476,576 were vaccinated with a rotavirus vaccine, 151,242 were 
unvaccinated) and followed during 2007, 2008, 2009, and/or 2010. The other 277,900 
children were born during the pre-vaccine period, May 2000-April 2005, and 
followed in 2001, 2002, 2003, 2004, and/or 2005.  Among all 627,818 children 
followed during the rotavirus vaccine period, 379,262 (60%) were followed during 
parts of two calendar years.   
Characteristics of cohort.  Almost 76% of the children born during the 
rotavirus vaccine period received at least one dose of RV5 or RV1 of which 79% 
completed the series.  Vaccination rates varied by calendar year, ranging from 51% in 
2007 to 86% in 2010 (Table 4).  Most (91%) vaccinated children received RV5, and 
over 3% received doses of RV5 and RV1.   
Nearly 4% of children were hospitalized overnight for a non-AGE diagnosis 
by age two months, and this percentage was slightly lower among the rotavirus-
vaccinated compared to the unvaccinated in 2009 and 2010.  The mean number of 
older siblings in each household was slightly lower in households with rotavirus-
vaccinated compared to unvaccinated children, but was stable across calendar years.   
Children residing in the Northeast, North-Central, and Western US had lower rates of 
rotavirus vaccination than children residing in the Southern US; children residing in 
the South also composed almost half of the entire study population.  Children residing 
in the Western US were better represented during the baseline years than in the
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 vaccine years (19% versus 11%).  In each calendar year, most children (86-89%) 
resided in metropolitan areas, with 66-69% of them residing in metropolitan areas 
with populations of one million persons or more.  There was a slight increase in the 
number of children residing in large metropolitan areas with each successive calendar 
year.  Children residing in metropolitan areas were 3 to 5% more likely than those 
residing in non-metropolitan areas to be vaccinated across each calendar year. 
RGE hospitalizations.  Twenty-three of 905,718 infants were dropped from 
the cohort because their cohort entry date (8 month birthday) equaled their cohort exit 
date (RGE hospitalization date, (n=4) or loss of health plan enrollment date, (n=19)). 
Among the 905,695 remaining children, 1016 (0.11%) were hospitalized for RGE 
during follow-up.   The percentage of infants and children hospitalized for RGE 
decreased during each calendar year or period as follows:  2001-2005, 722/277,899 
(0.26%); 2007, 63/133,309 (0.05 %); 2008, 114/266,941 (0.04%); 2009, 96/311,253 
(0.03%); 2010, 21/296,323 (0.01%).  The incidence rate of RGE hospitalization in 
March, the traditional peak of rotavirus activity, ranged from 121 per 10,000 child-
years during the pre-vaccine period to 1 per 10,000 child-years in 2010 (Figure6).  
The pattern of RGE hospitalization rates closely followed the pattern of rotavirus 
activity in reports published elsewhere (28-31). 
AGE hospitalizations.  Of the 905,678 infants whose cohort entry date did not 
equal their cohort exit date with regards to AGE hospitalizations, 4483 (0.49%) had 
an AGE diagnosis.  The percentage of infants and children hospitalized for AGE 
during the pre-vaccine years was 0.73% (2021/277,893).  This percentage declined to 
0.31% (413/133,306) in 2007 and continued to decline steadily during the vaccine
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 years, reaching 0.17% (507/296,120) in 2010.  Overall, nearly one-quarter of the 
AGE diagnoses were coded as RGE. However, the proportion of children with AGE 
diagnostic codes that corresponded to RGE generally decreased with each successive 
calendar year or period (2001-2005, 36% (722/2021); 2007, 15% (63/413); 2008, 
16% (114/730); 2009, 12% (96/812); 2010, 4% (21/507)). Despite the decline in the 
proportion of AGE diagnoses coded as RGE through the years, the monthly incidence 
rate of AGE by year followed a similar pattern as the monthly incidence rate of RGE 
by year (Figure 7).  
Rotavirus VE.  Direct VE of one or more doses of RV5 or RV1 in preventing 
RGE hospitalizations between ages 8 and 20 months ranged from 87 to 92% (Table 5, 
Figure 8).   The indirect VE varied more widely, from 14% (95% CI, -14-36%) in 
2007 to 82% (95% CI, 70-90%) in 2010 (Figure 9) .  Accounting for both direct and 
indirect VE among the rotavirus-vaccinated infants yielded a total VE estimate that 
increased from 91% (95% CI, 73-97%) in 2007 to 98% (95% CI, 96-99%) in 2010.  
The overall VE ranged from 40% (95% CI, 20-54%) in 2007 to 96% (93-97%) in 
2010 (Figure 10).  The overall VE estimates were low in 2007 compared to 2008-
2010, but the direct and total VE estimates were high (≥87%) across all four calendar 
years.   The rotavirus VE estimates were substantially lower in the prevention of AGE 
hospitalization, but generally followed a similar pattern as the VE estimates in the 
prevention of RGE hospitalization.  Notable exceptions included the direct VE 
estimates which increased through 2009 and then decreased in 2010, and the total VE 
estimates which increased four-fold from 2007 to 2008 (Table 6, Figures 8-10). 
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Absolute effects of rotavirus vaccination.  Under the assumption of perfect 
sensitivity and specificity of the RGE ICD-9-CM code, 31 to 33 RGE hospitalizations 
per 10,000 child-years were prevented in vaccinated children and 10 to 26 RGE 
hospitalizations per 10,000 child-years were prevented in unvaccinated children in 
our cohort during each calendar year, 2007- 2010 (among vaccinated infants, 6 to 21 
hospitalizations were prevented as a result of direct effects, while 10 to 26 
hospitalizations were prevented from indirect effects) (Table 7).  Irrespective of 
vaccination status and thus from a public health viewpoint, in order to prevent one 
RGE hospitalization in our cohort, 315 to 421 children required a rotavirus 
vaccination.   Assuming a more realistic scenario of 50% and 25% sensitivity of the 
RGE ICD-9 code, only 80 to 210 children may have required a rotavirus vaccination 
in order to prevent one RGE hospitalization.  Compared to estimates relying only on 
RGE diagnostic codes, using AGE diagnostic codes to estimate the number of RGE 
hospitalizations prevented in our cohort increased the number by 130-180% among 
rotavirus-vaccinated children each calendar year (Table 8).  
4. Discussion 
 
Receiving one or more doses of RV5 or RV1 was highly effective in 
preventing RGE hospitalizations in this population of commercially-insured US 
infants and children aged 8 to 20 months.  Direct VE was high across each calendar 
year, ranging from 87% in 2007 and 2008 to 92% in 2009, and indirect protection 
increased the VE among the rotavirus-vaccinated by an additional 3 to 8% each 
calendar year.    By comparison, in clinical trials, a complete series (three doses) of 
RV5 was 98% (95% CI, 88-100%) effective against severe RGE for the first full
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 rotavirus season post-vaccination, and a complete series (two doses) of RV1 was 
85% (95% CI, 70-94%) effective against hospitalizations for severe RGE from two 
weeks after the second dose until one year of age.(32, 33) Interestingly, our direct VE 
estimates were similar to the estimates calculated in the aforementioned clinical trials, 
despite the fact that 21% of the infants in our post-marketing study did not complete a 
rotavirus vaccine series.   In our view, this observation has two possible explanations.  
First, partial completion of a rotavirus vaccine series may still result in high direct 
VE.  This observation has been supported by other post-marketing studies, including  
an active, prospective population-based case-control study of laboratory-confirmed 
RGE hospitalizations and emergency department visits in three US counties  from 
January-June 2006-2009 where the direct VE of RV5 for one, two, and three dose 
rotavirus vaccine regimens was 74% (95% CI, 37-90%), 88% (95% CI, 66-96%), and 
87% (95% CI, 71-94%) in children <4 years of age, and another study that used a 
database from a large US health insurer to estimate one and two dose direct VE 
estimates in preventing RGE hospitalizations and emergency department visits for 
RV5 during the 2007 and 2008 rotavirus seasons (one-dose VE=88%, 95% CI,45-
99% and two-dose VE=94%, 95% CI,61-100%).(34, 35) The alternative explanation 
may be that our direct VE estimates are biased upward.    A mathematical model 
showed that when a vaccine provides indirect protection and the percent vaccinated in 
subpopulations is not equal (the likely scenario for most post-marketing studies), then 
direct VE estimates may be biased upward from clinical trial efficacy estimates 
because the vaccinated sub-population will receive more indirect protection than the 
unvaccinated sub-population, assuming that there are no other differences between
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 the vaccinated and unvaccinated groups.(36)   In our study, this bias would have 
increased during the later years when the percentage of rotavirus-vaccinated children 
was highest which could explain why the direct VE estimates in our cohort in 2009 
and 2010 were 5 and 3% higher than in 2007 and 2008.  Thus, it is important to 
realize that our direct VE estimates may in fact have included indirect benefits, and 
that the importance of indirect benefits in rotavirus-vaccinated children may have 
been further underscored in the total VE estimate since the direct VE was already 
high and VE cannot exceed 100%.  Supporting the importance of indirect protection 
among rotavirus-vaccinated children was our result which showed that the direct VE 
estimates underestimated the total number of RGE hospitalizations prevented by 1.5 
to 5.3-fold even though the direct VE estimate was only 3 to 8% lower than the total 
VE estimate. 
We expected indirect or herd protection against RGE hospitalizations to 
increase with each successive calendar year from 2007 to 2010, but this was not the 
case.  The calendar year 2009 had a slightly lower indirect VE estimate than 2008 
(44% versus 40%).  Although a lack of difference between these indirect VE 
estimates cannot be ruled out since their confidence intervals overlap, the apparent 
decline of indirect VE in 2009 is worth further consideration.  Not only a decline, but 
a total absence of indirect protection from the rotavirus vaccine during the 2009 
rotavirus season has been observed in other studies.(25, 37, 38), and it has been 
hypothesized that the low levels of rotavirus activity during the 2008 season allowed 
unvaccinated children to pass through the season without exposure to wild-type virus 
until 2009.(37)  However, since rotavirus activity in the US was also curtailed in 2009
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 and the indirect VE estimate more than doubled to 82% in 2010, additional 
explanations may be needed.(39)  A study modeling direct and indirect transmission 
dynamics of rotavirus vaccination in England and Wales found that assuming 90% 
rotavirus vaccination coverage, indirect effects would reduce RGE 1.8-2.9 times more 
than expected from direct effects during the first year after initiation of a vaccination 
program, but that over a 5-year period, the indirect benefits would decline.(40)  
Additional years of follow-up and other data sources may be needed to better 
establish time trends related to the indirect effectiveness of rotavirus vaccination in 
the US.   Nonetheless, due to the demonstrated importance of indirect VE among both 
vaccinated and unvaccinated children, we recommend that the indirect effectiveness 
of vaccines be measured prior to the post-market phase when possible.  This is 
especially important for candidate vaccines with limited direct VE, but potentially 
strong indirect VE (e.g., cholera vaccines, rotavirus vaccines in certain developing 
countries).(41, 42)   
Our study has two important strengths.  First, across both time and vaccination 
status, the five calendar years or periods we examined were generally well balanced 
on selected covariates which included proxies for health, potential sources of 
rotavirus infections, and population-level rotavirus vaccination coverage and mixing 
patterns.  Since all cohort members were commercially insured and required to have 
at least one outpatient record during infancy as well as at least one dose of DTaP, 
such standards may have led to the relatively good balance between the groups with 
regards to the measured, and hopefully, unmeasured potential confounders.  Second, 
since we used Cox proportional hazards regression, our analyses inherently adjusted
   
65 
 
 
for age and we also stratified by year to account for increasing vaccination coverage 
and adjusted for month of birth to account for the changing seasonality of rotavirus 
over the study period.   Further adjustment using the covariates we described in Table 
1 did not appreciably change our VE estimates so they were not presented.  This lack 
of change was not surprising since our groups seemed reasonably well balanced.   
Our results should be interpreted with some caution due to four possible 
limitations. First, the RGE ICD-9-CM code likely had low sensitivity which would 
bias the number of RGE hospitalizations prevented downward.  Thus, we conducted 
sensitivity analyses on the number of RGE hospitalizations prevented assuming 25% 
and 50% sensitivity of the RGE ICD-9-CM code.(21, 43)  These analyses made 
assumptions that may not have been entirely realistic, including that the sensitivity 
did not vary over time or between vaccinated and unvaccinated children and that 
estimates of 25 and 50% sensitivity and 100% specificity were reasonable.   AGE 
ICD-9-CM diagnostic codes were also subject to low sensitivity.  A recent study 
conducted at three US children’s hospitals found that only 52% of children 
hospitalized with AGE received a qualifying diagnostic code at discharge.(44)  
Fortunately, low sensitivity of RGE or AGE ICD-9-CM codes would not bias VE 
estimates if specificity was high which was assumed based on research as well as 
other studies showing similar RGE and AGE hospitalization patterns as our study. 
(21,23, 29-31)  Second, we limited the age range of follow-up to infants and children 
8 to 20 months.  Some studies suggest that the US rotavirus vaccination program may 
have increased the mean age at which infants and children are first infected with 
rotavirus, and thus potentially hospitalized with RGE.(45, 46)  If the shift in mean age
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has been dramatic, the rotavirus vaccines in the later years (e.g., 2010) may appear 
more effective overall than in the earlier years simply because the burden of RGE 
hospitalization has shifted to older age groups.  A US strain surveillance study of 919 
EIA-confirmed RGE cases found that while the mean age of cases was 13.1 and 13.3 
months during the 2005-2006 and 2006-2007 rotavirus seasons, the mean age of cases 
increased to 17.7 months during the 2007-2008 rotavirus season.(46) Despite this 
potential shift, our study would still accurately document  rotavirus VE among 8 to 20 
month olds, and since RGE hospitalizations are generally considered most serious in 
very young children (e.g., <2 years), our study would still have captured many of the 
most clinically significant cases.  Third, our study considered infants receiving any 
number of doses of rotavirus vaccine as “vaccinated” and did not compare the direct 
VE of RV5 to RV1 due to the limited number of infants vaccinated with RV1. A few 
comparative effectiveness studies as well as studies assessing partial rotavirus vaccine 
effectiveness have been published, and ongoing monitoring should continue to assess 
these questions.(35, 41, 47-50) Finally, our study may have limited generalizability 
since it involved only US infants and children with commercial insurance, and did not 
include those with Medicaid insurance or the uninsured population.  However, our 
study is one of the largest rotavirus VE studies to-date, and assesses effectiveness in 
the population of infants and children most likely to receive the rotavirus vaccines in 
the US.   
If a vaccine has high direct VE, such measurements may only slightly 
underestimate the total VE which also account for indirect protection among 
vaccinated persons.  However, failing to account for indirect VE may severely
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underestimate the impact of important public health outcomes, such as the absolute 
number of RGE hospitalizations prevented among vaccinated children in our cohort.  
For this reason, VE studies should strive to provide both direct and indirect VE 
estimates, and also report results in the context of absolute benefits. 
  
  
 
5. Figures and Tables 
 
      FIGURE 4.  Types of Vaccine Effectiveness as Described by Halloran et al 
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FIGURE 5.  Cohort Study Design for Rotavirus Vaccine 
Population of Commercially Insured Infants and Children 8 to 20 Months, 2007
Abbreviations:  DTaP, diphtheria, tetanus, and acellular pertussis vaccine; ICD
International Classification of Diseases, 9
RV5, pentavalent rotavirus vaccine  
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TABLE 4.  Characteristics of Commercially Insured US Infants and Children Vaccinated or Unvaccinated with RV5 or 
RV1, 2001-2010 (n=905,718)  
 
 2007* 2008* 2009* 2010* 2001-2005 
Variable V Not V V Not V V Not V V Not V  
Overall 68,380 
(51.29) 
64,932 
(48.71) 
175,768 
(65.92) 
90,883 
(34.08) 
249,840 
(80.34) 
61,136 
(19.66) 
254,249 
(85.85) 
41,892 
(14.15) 
277,900 (100) 
Male 34,807 
(51.05) 
33,380 
(48.95) 
89,376 
(65.67) 
46,719 
(34.33) 
127,673 
(80.20) 
31,521 
(19.80) 
130,331 
(85.69) 
21,768 
(14.31) 
143,275 
 
Hospitalized overnight for non-
AGE, <2 months 
2,744 
(51.71) 
2,563 
(48.29) 
6,856 
(65.28) 
3,647 
(34.72) 
8,995 
(78.53) 
2,459 
(21.47) 
8793 
(83.89) 
1689 
(16.11) 
10,849 
Mean number of siblings (std) 0.81 
(0.97) 
0.88 
(1.02) 
0.81 
(0.98) 
0.90 
(1.04) 
0.80 
(0.98) 
0.93 
(1.09) 
0.76 
(0.96) 
0.91 
(1.09) 
0.85  
(1.04) 
Region of residence           
    Northeast 4,692 
(43.40) 
6,119 
(56.60) 
14,799 
(59.99) 
9,869 
(40.01) 
28,395 
(73.60) 
10,183 
(26.40) 
35,312 
 (79.33) 
9203 
 (20.67) 
28,956 
    North-Central 21,296 
(48.66) 
22,473 
(51.34) 
52,672 
(62.73) 
31,299 
(37.27) 
70,875 
(78.87) 
18,988 
(21.13) 
70,936 
(86.35) 
11,211 
(13.65) 
67,895 
    South 36,568 
(56.21) 
28,488 
(43.79) 
91,886 
(70.72) 
38,050 
(29.28) 
125,634 
(83.96) 
24,003 
(16.04) 
117,518 
(88.29) 
15,593 
(11.71) 
127,956 
    West 5,824 
(42.59) 
7,852 
(57.41) 
16,411 
(58.45) 
11,665 
(41.55) 
24,936 
(75.80) 
7,962 
(24.20) 
30,483 
(83.82) 
5885 
(16.18) 
53,093 
Population density of residence          
     Metro with ≥1 million population 38,636 
(50.34) 
38,108 
(49.66) 
102,075 
(66.22) 
52,069 
(33.78) 
150, 601 
(80.94) 
35,456 
(19.06) 
156,027 
(86.17) 
25,046 
(13.83) 
160,282 
     Metro with 250,000 – 1 million 
__ population 
13,173 
(54.97) 
10, 789 
(45.03) 
33,515 
(68.75) 
15,231 
(31.25) 
45,440 
(82.48) 
9,650 
(17.52) 
47,219 
(87.45) 
6777 
(12.55) 
54,512 
     Metro with <250,000 population  8,095 
(56.63) 
6,199 
(43.37) 
18,443 
(67.48) 
8,890 
(32.52) 
24,680 
(80.98) 
5,796 
(19.02) 
23,780 
(86.32) 
3769 
(13.68) 
27,543 
     Urban with ≥20,000 population, 
__ adjacent to metro area 
2,613 
(49.43) 
2,673 
(50.57) 
6,375 
(62.97) 
3,749 
(37.03) 
8,376 
(76.77) 
2,535 
(23.23) 
8274 
(83.05) 
1689 
(16.95) 
10,412 
     Urban with ≥20,000 population, 
__ not adjacent to metro area 
1,197 
(42.52) 
1,618 
(57.48) 
3,165 
(57.35) 
2,354 
(42.65) 
4,120 
(73.69) 
1,471 
(26.31) 
3722 
(80.72) 
889 
(19.28) 
5225 
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Abbreviations:  AGE, acute gastroenteritis; IQR, interquartile range; Metro, metropolitan; RV1, monovalent rotavirus vaccine; RV5,pentavalent 
rotavirus vaccine; Std, standard deviation; V, vaccinated 
*379,262 (60%) of infants and children were counted during two consecutive calendar years during the vaccine period, 2007-2010.   
  AGE as opposed to RGE cohort used for counts. 
 
 
     Urban with 2500-19,999  __ __ 
__population, adjacent to metro __  
__area 
2,744 
(46.44) 
3,165 
(53.56) 
7,147 
(59.75) 
4,814 
(40.25) 
9,641 
(74.49) 
3,302 
(25.51) 
9055 
(81.42) 
2067 
(18.58) 
11,909 
     Urban with 2500-19,999 
__population, not adjacent to metro 
__area 
1,266 
(42.09) 
1,687 
(57.91) 
3,263 
(54.68) 
2,704 
(45.32) 
4,530 
(68.22) 
2,110 
(31.78) 
3981 
(76.47) 
1225 
(23.53) 
4981 
     Rural or <2500 population,  
     adjacent to metro area 
394 
(52.12) 
362 
(47.88) 
951 
(64.74) 
518 
(35.26) 
1,351 
(78.27) 
375 
(21.73) 
1258 
(87.42) 
181 
(12.58) 
1673 
     Rural or <2500 population, 
     not adjacent  to metro area 
302 
(47.71) 
331 
(52.29) 
834 
(60.09) 
554 
(39.91) 
1,101 
(71.40) 
441 
(28.60) 
933 
(78.93) 
249 
(21.07) 
1363 
  
 
FIGURE 6.  Incidence of RGE Hospitalizations per 10,000 Child
Commercially Insured US Infants and Children 8 to 20 Months, 2001
Abbreviations:  RGE, rotavirus gastroenteritis
 
 
  
72 
-years Among 
-2010
 
 
 
 
  
  
 
FIGURE 7.  Incidence of AGE Hospitalizations per 10,000 
Commercially Insured US Infants and Children 8 to 20 Months, 2001
Abbreviations:  AGE, acute gastroenteritis
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TABLE 5.  Rotavirus vaccine effectiveness estimates against RGE hospitalization in US Commercially Insured Infants and 
 Children 8 to 20 Months, 2007-2010 
 Direct effectiveness Indirect effectiveness Total effectiveness Overall effectiveness 
Calendar 
Year 
Percent 
vaccinated 
with ≥1 
dose of 
RV5 or RV1 
Unadjusted 
VE (95% CI) 
Number of 
events/people 
in numerator 
Unadjusted 
VE (95% CI) 
Number of 
events/people 
in numerator 
Unadjusted 
VE (95% CI) 
Number of 
events/people 
in numerator 
Unadjusted 
VE (95% CI) 
Number of 
events/people 
in numerator 
Number of 
events/people 
denominator 
Number of 
events/people 
denominator 
Number of 
events/people 
denominator 
Number of 
events/people 
denominator 
2007 51.3 87 
 58, 96 
3/68,380 14 
 -14, 36 
60/64,929 91  
73, 97 
3/68,380 40 
 20, 54 
63/133,309 
60/64,929 722/277,899 722/277,899 722/277,899 
2008  65.9 87  
80, 92 
23/175,890 44  
30, 55 
91/91,051 92  
88, 95 
23/175,890 75  
69, 79 
114/266,941 
91/91,051 722/277,899 722/277,899 722/277,899 
2009 80.3 92  
87, 95 
22/250,035 40  
24, 53 
74/61,218 95  
92, 97 
22/250,035 83  
79, 86 
96/311,253 
74/61,218 722/277,899 722/277,899 722/277,899 
2010 85.9 90  
75, 96 
8/254,377 82  
70, 90 
13/41,946 98  
96, 99 
8/254,377 96  
93, 97 
21/296,323 
13/41,946 722/277,899 722/277,899 722/277,899 
Abbreviations:  CI, confidence interval; RGE, rotavirus gastroenteritis; RV1, monovalent rotavirus vaccine; RV5, pentavalent  
rotavirus vaccine; VE, vaccine effectiveness 
   
    
  
7
5
 
TABLE 6.  Rotavirus vaccine effectiveness estimates against AGE hospitalization in US Commercially Insured Infants and  
Children 8 to 20 Months, 2007-2010 
 Direct effectiveness Indirect effectiveness Total effectiveness Overall effectiveness 
Calendar 
Year 
Percent 
vaccinated 
with ≥1 
dose of 
RV5 or RV1 
Unadjusted 
VE (95% CI) 
Number of 
events/people 
in numerator 
Unadjusted 
VE (95% CI) 
Number of 
events/people 
in numerator 
Unadjusted 
VE (95% CI) 
Number of 
events/people 
in numerator 
Unadjusted 
VE (95% CI) 
Number of 
events/people 
in numerator 
Number of 
events/people 
denominator 
Number of 
events/people 
denominator 
Number of 
events/people 
denominator 
Number of 
events/people 
denominator 
2007 51.3 22  
3, 37 
142/68,378 -8 
 -24, 6 
271/64,928 12  
-5, 27 
142/68,378 0  
-13, 11 
413/133,306 
271/64,928 2021/277,893 2021/277,893 2021/277,893 
2008  65.9 40  
30, 48 
413/175,765 24  
15, 33 
317/90,882 48  
43, 53 
413/175,765 40  
35, 45 
730/266,647 
317/90,882 2021/277,893 2021/277,893 2021/277,893 
2009 80.3  56  
49, 62 
512/249,838 9  
-3, 19 
300/61,136 59 
 54, 62 
512/249,838 48  
44, 52 
812/310,974 
300/61,136 2021/277,893 2021/277,893 2021/277,893 
2010 85.9 41 
27, 53 
398/254,232 45 
 33, 54 
109/41,888 65 
 62, 69 
398/254,232 62  
58, 66 
507/296,120 
109/41,888 2021/277,893 2021/277,893 2021/277,893 
Abbreviations:  AGE, acute gastroenteritis; CI, confidence interval; RV1, monovalent rotavirus vaccine; RV5, pentavalent rotavirus  
vaccine; VE, vaccine effectiveness 
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TABLE 7.  Absolute Numbers of RGE Hospitalizations Prevented by the Rotavirus Vaccination Program in Commercially  
Insured US Infants and Children 8 to 20 Months, 2007-2010 
Calendar year Observed 
number of RGE 
hospitalizations 
in numerator  
Number of 
person-years in 
numerator 
Observed 
number of RGE 
hospitalizations 
in denominator  
Number of  
person-years in 
denominator 
Observed IRD 
per 10,000 
person-years  
95% confidence 
interval for IRD 
Direct Effectiveness       
2007 3 28,249.81 60 37,791.09 -14.81 -10.62, -19.01 
2008 23 85,451.55 91 39,447.11 -20.38 -15.51, -25.24 
2009 22 131,381.27 74 32,292.04 -21.24 -15.97, -26.51 
2010 8 118,708.19 13 18,980.99 -6.18 -2.42,   -9.93 
Indirect Effectiveness       
2007 60 37,791.09 722 216,767.00 -17.43 -12.74, -22.13 
2008 91 39,447.11 722 216,767.00 -10.24 -4.91, -15.56 
2009 74 32,292.04 722 216,767.00 -10.39 -4.63, -16.15 
2010 13 18,980.99 722 216,767.00 -26.46 -22.01, -30.90 
Total Effectiveness       
2007 3 28,249.81 722 216,767.00 -32.25 -29.54, -34.96 
2008 23 85,451.55 722 216,767.00 -30.62 -27.95, -33.28 
2009 22 131,381.27 722 216,767.00 -31.63 -29.10, -34.16 
2010 8 118,708.19 722 216,767.00 -32.63 -30.16, -35.11 
Overall Effectiveness       
2007 63 66,040.89 722 216,767.00 -23.77 -20.38, -27.15 
2008 114  124,898.67 722 216,767.00 -24.18 -21.23, -27.13 
2009 96 163,673.32 722 216,767.00 -27.44 -24.74, -30.14 
2010 21 137,689.17 722 216,767.00 -31.78 -29.27, -34.30 
Abbreviations:  IRD, incidence rate difference; RGE, rotavirus gastroenteritis 
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TABLE 8.  Absolute Numbers of AGE Hospitalizations Prevented by the Rotavirus Vaccination Program in Commercially  
Insured US Infants and Children 8 to 20 Months, 2007-2010   
Calendar year Observed 
number of AGE 
hospitalizations 
in numerator  
Number of 
person-years in 
numerator 
Observed 
number of AGE 
hospitalizations 
in denominator  
Number of  
person-years in 
denominator 
Observed IRD 
per 10,000 
person-years  
95% confidence 
interval for IRD 
Direct Effectiveness 
2007 142 28,208.94 271 37,696.19 -21.55 -9.64, -33.46 
2008 413 85,258.80 317 39,319.23 -32.18 -22.15, -42.21 
2009 512 131,095.68 300  32,165.02 -54.21 -43.13, -65.30 
2010 398 118,519.67 109 18,932.48 -23.99 -12.69, -35.29 
Indirect Effectiveness    
2007 271 37,696.19 2021 216,117.07 -21.62 -12.14, -31.10 
2008 317 39,319.24 2021 216,117.07 -12.89 -3.13, -22.66 
2009 300  32,165.02 2021 216,117.07 -0.25 -11.56,  11.07 
2010 109 18,932.48 2021 216,117.07 -35.94 -24.39, -47.49 
Total Effectiveness    
2007 142 28,208.94 2021 216,117.07 -43.18 -33.95, -52.40 
2008 413 85,258.80 2021 216,117.07 -45.07 -38.87, -51.27 
2009 512 131,095.68 2021 216,117.07 -54.46 -49.16, -59.76 
2010 398 118,519.67 2021 216,117.07 -59.93 -54.69, -65.18 
Overall Effectiveness    
2007 413 65,905.13 2021 216,117.07 -30.85 -23.56, -38.14 
2008 730 124,578.04 2021 216,117.07 -34.92 -29.03, -40.81 
2009 812 163,260.70 2021 216,117.07 -43.78 -38.46, -49.10 
2010 507 137,452.15 2021 216,117.07 -56.63 -51.44, -61.82 
Abbreviations:  AGE, acute gastroenteritis; IRD, incidence rate difference 
  
 
FIGURE 8.  Benefit of Rotavirus Vaccine in Preventing RGE and AGE 
Hospitalizations Among Commercially Insured US Children 8 to 20 Months 
Receiving at Least One Dose of Rotavirus Vaccine, 2007
Abbreviations:  AGE, acute gastroenteritis; RGE, rotavirus gastroenteritis
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FIGURE 9.  Benefit of Rotavirus Vaccine Use in the General Population in 
Preventing RGE and AGE Hospitalizations Among Commercially Insured US 
Children 8 to 20 Months Not 
Abbreviations:  AGE, acute gastroenteritis; RGE, rotavirus gastroenteritis
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FIGURE 10.  Public Health Benefit of Rotavirus Vaccine Use in Preventing RGE 
and AGE Hospitalizations Among Commercially Insured US Children 8 to 20 
Months, 2007-2010 
Abbreviations:  AGE, acute gastroenteritis; RGE, rotavirus gastroenteritis
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CHAPTER V 
CONCLUSIONS 
 
A. Recapitulation of overall study aims, findings and degree to which the goals of the 
doctoral research have been met 
 
1.  Determine predictors of rotavirus vaccine initiation and completion. 
 
 Comment.  The strongest predictors of both rotavirus vaccine series initiation and 
completion were receipt of DTaP and visiting a pediatrician versus family physician. 
Since most children who received a rotavirus also received at least one other 
recommended childhood vaccine (e.g., DTaP), it appears that neither parents nor 
providers are “cherry-picking” vaccines.  Rather, it appears that infants either generally 
receive the recommended childhood vaccines or do not.  This observation is further 
supported by a post-hoc analysis that found a high correlation between the number of 
doses of DTaP (one, two, or three) and number of doses of RV5 (one, two, or three) 
received among infants in our cohort (r=0.76).   Since our cohort consisted of infants with 
private insurance who had at least one outpatient record, failure to access the healthcare 
system cannot fully explain why some infants did not receive recommended vaccines, 
such as DTaP or rotavirus.  Based on our results, interventions aimed at increasing the 
coverage of any one childhood vaccine may help increase the coverage and timeliness of 
other recommended childhood vaccines, assuming that vaccine availability is not an 
issue.  This was shown to be the case for the DTaP vaccine in Australia, where the third
dose coverage of DTaP vaccine in a pre-RV5 cohort was 80%, but increased by 5 to 12 
percent once the RV5 vaccine was available and widely used.(1)    
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Education interventions, particularly those targeted at family physicians should be 
considered.  This recommendation is consistent with the results of a 2007 nationally-
representative survey of pediatricians and family physicians which found that 
pediatricians were much more likely to administer the rotavirus vaccine to eligible infants 
than family physicians, possibly because family physicians were more concerned with 
vaccine safety and adding additional vaccines to the childhood schedule than 
pediatricians.(2)  Studies examining other vaccines in various populations of infants and 
young children have also shown that family physicians may be less likely to adopt and 
may be less knowledgeable about vaccine recommendations than pediatricians.(3)  
     A priori, we predicted that population size and density of an infant’s residence 
would also be an important predictor of vaccine series initiation and completion.   While 
infants residing in rural and small urban areas were less likely to be vaccinated than those 
residing in large metropolitan areas in our study, they were also underrepresented which 
limited study power.  A dataset that includes a more geographically diverse cohort of 
infants is necessary to further explore this factor further.   
2. Assess timeliness of rotavirus vaccine administration as per the 2009 Advisory 
Committee on Immunization Practices (ACIP) guidelines 
Comment.  Overall, adherence to the 2009 ACIP guidelines for rotavirus vaccine 
administration was high.  Although we compared all years of data (2006 to 2010) to the 
2009 ACIP guidelines which are less stringent than the 2006 ACIP guidelines, adherence 
remained high even when we reanalyzed our data using the 2006 ACIP guidelines (data 
not shown). 
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     Despite overall high levels of compliance to the 2009 ACIP recommendations, 
ensuring that infants complete the rotavirus vaccine series could be improved.  Other 
multi-dose vaccines face a similar challenge.  Prior to rotavirus vaccine availability, the 
vaccination histories of over 17,000 children in the 2005 NIS were reviewed, revealing 
that of the 28% of children not compliant with ACIP recommendations, two-thirds were 
categorized as such because they were missing doses for multi-dose vaccinations.(4)  
However, since vaccination coverage has been shown to increase as the number of 
physician office visits increase, one remedy physicians could consider is vaccinating 
infants at-risk for missing office visits with RV1 since it requires only two doses to 
complete the series.(5)  However, since identifying infants at-risk for missing office visits 
can be difficult, this recommendation may only be practical in theory.  Furthermore, post-
marketing data comparing partial series effectiveness of RV5 to RV1 are limited.(6) 
3.   Estimate the direct, indirect, total, and overall rotavirus vaccine effectiveness (VE) 
against rotavirus gastroenteritis (RGE)  and acute gastroenteritis (AGE) hospitalizations 
among those aged 8 to 20 months over the life course of the vaccines 
Comment .  Receiving one or more doses of RV5 or RV1 was highly effective in 
preventing RGE hospitalizations in this population of commercially-insured US infants 
and children aged 8 to 20 months.  Direct VE was high across each calendar year, ranging 
from 87% in 2007 and 2008 to 92% in 2009, and indirect protection increased the VE 
among the rotavirus-vaccinated by an additional 3 to 8% each calendar year.  Overall VE 
estimates ranged from 40 to 96% each calendar year. 
We expected indirect or herd protection against RGE hospitalizations to increase with 
each successive calendar year from 2007 to 2010, but this was not the case.  The calendar
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year 2009 had a slightly lower indirect VE estimate than 2008 (44% versus 40%).  
Although a lack of difference between these indirect VE estimates cannot be ruled out 
since their confidence intervals overlap, the apparent decline of indirect VE in 2009 is 
worth further consideration.  Not only a decline, but a total absence of indirect protection 
from the rotavirus vaccine during the 2009 rotavirus season has been observed in other 
studies, and it has been hypothesized that the low levels of rotavirus activity during the 
2008 season allowed unvaccinated children to pass through the season without exposure 
to wild-type virus until 2009.(7-9) 
4. Calculate the absolute rate reductions of RGE and AGE hospitalizations attributable to 
the rotavirus vaccine or the rotavirus vaccine program in those aged 8 to 20 months 
Comment.  Under the assumption of perfect sensitivity and specificity of the RGE 
ICD-9-CM code, 31 to 33 RGE hospitalizations per 10,000 child-years were prevented in 
vaccinated children and 10 to 26 RGE hospitalizations per 10,000 child-years were 
prevented in unvaccinated children in our cohort during each calendar year, 2007- 2010.  
Failure to account for indirect protection in the rotavirus-vaccinated population 
underestimated the number of hospitalizations 1.5 to 5.3-fold.   
 
B. Strengths  
 
This dissertation has several strengths.  For both the patterns of use and VE study, our 
population was limited to infants and children with commercial insurance.  Since 
providers of such patients must report the vaccinations they administer in order to receive 
reimbursement, rotavirus vaccines were likely coded if given, and conversely, likely 
uncoded if not given.  However, to further increase specificity, all CPT vaccine codes 
were required to have a corresponding date of service, and states with reported universal 
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vaccination programs that include RV5 or RV1 (Alaska, Idaho, Massachusetts, 
Maine, North Dakota, New Hampshire, New Mexico, Oregon, Rhode Island, Vermont, 
Washington, Wisconsin, Wyoming) and were excluded.(10)  Thus, although we cannot 
verify that rotavirus vaccine misclassification was extremely limited, we have strong 
reason to believe that this was the case. 
With regards to the VE study, our study has two important strengths.  First, across 
both time and vaccination status, the five calendar years or periods we examined were 
generally well balanced on selected covariates which included proxies for health, 
potential sources of rotavirus infections, and population-level rotavirus vaccination 
coverage and mixing patterns.  Since all cohort members were commercially insured and 
required to have at least one outpatient record during infancy as well as at least one dose 
of DTaP, such standards may have led to the relatively good balance between the groups 
with regards to the measured, and hopefully, unmeasured potential confounders.  Second, 
since we used Cox proportional hazards regression, our analyses inherently adjusted for 
age and we also stratified by year to account for increasing vaccination coverage and 
adjusted for month of birth to account for the changing seasonality of rotavirus over the 
study period.   Further adjustment using the covariates we described in Table 1 did not 
appreciably change our VE estimates so they were not presented.  This lack of change  
was not surprising since our groups seemed reasonably well balanced.   
          C. Limitations 
  Our patterns of use analyses are subject to limitations.  Many variables potentially 
predictive of rotavirus vaccine uptake were not available in our data.  Further research 
is needed to examine the effect of potentially relevant predictors, such as race, 
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ethnicity, family economic status, and physician reimbursement levels. We were 
unable to validate important estimated dates, such as birth dates and rotavirus 
vaccination dates.  While such misclassifications could affect the results of our 
analysis that assesses adherence to the 2009 ACIP recommendations, we do not 
suspect that there was enough misclassification to affect our overall conclusions and 
they are consistent with the results from another recently published study.(11)  As 
mentioned earlier in the discussion, the infants in our cohorts were not representative 
of the US infant population; however, our study included nearly 600,000 infants with 
commercial insurance who may represent the group of infants that most commonly 
utilizes the rotavirus vaccines.       
Our results from the VE study should be interpreted with caution due to four main 
limitations. First, the RGE ICD-9-CM code likely had low sensitivity which would bias 
the number of RGE hospitalizations prevented downward.  Thus, we conducted 
sensitivity analyses on the number of RGE hospitalizations prevented assuming 25% and 
50% sensitivity of the RGE ICD-9-CM code.(12, 13) These analyses made assumptions 
that may not have been entirely realistic, including that the sensitivity did not vary over 
time or between vaccinated and unvaccinated children and that estimates of 25 and 50% 
sensitivity and 100% specificity were reasonable.   AGE ICD-9-CM diagnostic codes 
were also subject to low sensitivity.  A recent study conducted at three US children’s 
hospitals found that only 52% of children hospitalized with AGE received a qualifying 
diagnostic code at discharge.(14)  Fortunately, low sensitivity of RGE or AGE ICD-9-
CM codes would not bias VE estimates if specificity was high which was assumed based 
on research as well as other studies showing similar RGE and AGE hospitalization
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patterns as our study.(12,  15-18)  Second, we limited the age range of follow-up to 
infants and children between 8 and 20 months.  Some studies suggest that the US 
rotavirus vaccination program may have increased the mean age at which infants and 
children are first infected with rotavirus, and thus potentially hospitalized with RGE.(19, 
20)  If the shift in mean age has been dramatic, the rotavirus vaccines in the later years 
(e.g., 2010) may appear more effective overall than in the earlier years simply because 
the burden of RGE hospitalization has shifted to older age groups.  A US strain 
surveillance study of 919 EIA-confirmed RGE cases found that while the mean age of 
cases was 13.1 and 13.3 months during the 2005-2006 and 2006-2007 rotavirus seasons, 
the mean age of cases increased to 17.7 months during the 2007-2008 rotavirus 
season.(20)  Despite this potential shift, our study would still accurately document  
rotavirus VE among 8 to 20 month olds, and since RGE hospitalizations are generally 
considered most serious in very young children (e.g., <2 years), our study would still 
have captured many of the most clinically significant cases.  Third, our study considered 
infants receiving any number of doses of rotavirus vaccine as “vaccinated” and did not 
compare the direct VE of RV5 to RV1 due to the limited number of infants vaccinated 
with RV1. A few comparative effectiveness studies as well as studies assessing partial 
rotavirus vaccine effectiveness have been published, and ongoing monitoring should 
continue to assess these questions.(6, 20-25)   Finally, as was the case for our patterns of 
use study, our VE study may have limited generalizability since it involved only US 
infants and children with commercial insurance, and did not include those with Medicaid 
insurance or the uninsured population.  However, our study is one of the largest rotavirus
   
93 
  
 
 VE studies to-date, and assesses effectiveness in the population of infants and children 
most likely to receive the rotavirus vaccines in the US.   
D. Public Health Implications  
 Our first study revealed rapid initial uptake of the vaccine after RV5 was first 
licensed.  However, even several years after licensure, many children still did not 
receive the vaccine or received an incomplete series.  Quality improvement efforts 
should focus on ensuring that (1) infants complete the two-dose series for RV1 and 
three-dose series for RV5 or a mixed series; (2) family physicians receive the 
adequate education and support necessary to increase the rates of vaccination among 
infants in their care; and (3) other recommended infant vaccinations are administered. 
In addition to confirming the direct and indirect effectiveness of the rotavirus vaccines, 
our second study revealed several points to consider when estimating VE both pre- and 
post-market.  Due to the demonstrated importance of indirect VE, we recommend that the 
indirect impact of vaccines be measured prior to the post-market phase, if possible.  This 
is especially important for candidate vaccines with limited direct VE, but potentially 
strong indirect VE (e.g., cholera vaccines, rotavirus vaccines in certain developing 
countries).  Using geographic variations in vaccination coverage may help clinical trials 
measure the indirect impact of vaccinations, and thus provide better estimates of the real-
world impact of a vaccine before it is marketed.(26)  
    If a vaccine has high direct VE, such measurements may only slightly underestimate 
the total VE which also account for indirect protection among vaccinated persons.  
However, failing to account for indirect VE may severely underestimate the impact of 
important public health outcomes, such as the absolute number of RGE hospitalizations
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prevented among vaccinated children.  For this reason, VE studies should strive to 
provide both direct and indirect VE estimates, and also report results in the context of 
absolute benefits 
E. Future Directions 
  Research is ongoing and several exciting studies are planned with potential support 
from a R21 grant on vaccine safety.  First, in an effort to increase generalizability, we 
plan to conduct a feasibility study using the North Carolina Division of Medicaid 
Assistance Claims data.  Since children with Medicaid insurance automatically qualify 
for the federally funded Vaccines For Children (VFC) program which limits provider 
reimbursement for many vaccines, including rotavirus vaccines, to administrative 
charges, we predict that RV5 and RV1 codes will be underreported in Medicaid claims 
data.  However, since the rotavirus vaccine is the only routinely administered oral 
vaccine in the U.S., the use of oral vaccine administration codes offers potential 
opportunities to study patterns of uptake, effectiveness, and safety of the rotavirus 
vaccines in Medicaid claims data.  In addition, although we cannot link MarketScan data 
directly to patient medical records, we will attempt to externally validate the rotavirus 
vaccine codes and RGE and AGE codes using the North Carolina Immunization Registry 
(NCIR) and the North Carolina Disease Event Tracking and Epidemiologic Research 
Tool (NC DETECT).  Finally, we plan to compare the safety of RV5 and RV1 among 
infants by calculating the relative risks for intussusception and other potential adverse 
events identified through data mining, and determine whether patients vaccinated on 
alternative vaccine schedules or failing to complete the vaccine series have an increased 
risk for adverse events.  We predict that small elevated risks of intussusception
   
95 
  
 
  immediately following vaccination will be identified in both vaccines, but safety patterns 
among infants vaccinated by alternative schedules versus the recommended schedule, and 
infants enrolled in Medicaid versus commercial insurance, will be similar.  
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